Pacific Biosciences of California (PACB) 10-K 12 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 03, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	PACB
Entity Registrant Name	PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Entity Central Index Key	1299130
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$315,556,000
Entity Common Stock, Shares Outstanding		74,516,357

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets
Cash and cash equivalents	$36,449	$26,362
Investments	64,899	86,166
Accounts receivable	3,406	2,746
Inventory, net	11,335	10,050
Prepaid expenses and other current assets	1,671	1,135
Total current assets	117,760	126,459
Property and equipment, net	6,601	9,236
Other long-term assets	162	490
Total assets	124,523	136,185
Current liabilities
Accounts payable	5,608	1,717
Accrued expenses	11,441	7,905
Deferred service revenue, current	6,121	4,046
Deferred contractual revenue, current	6,785	6,785
Other liabilities, current	1,534	2,102
Total current liabilities	31,489	22,555
Deferred service revenue, non-current	1,129	518
Deferred contractual revenue, non-current	19,735	26,519
Other liabilities, non-current	2,153	3,517
Notes payable	14,124	13,347
Financing derivative	944	549
Total liabilities	69,574	67,005
Commitments and contingencies (Note 8)
Stockholders' equity
Preferred Stock, $0.001 par value: Authorized 50,000 shares; No shares issued or outstanding
Common Stock, $0.001 par value: Authorized 1,000,000 shares; Issued and outstanding 73,927 and 66,275 shares at December 31, 2014 and 2013, respectively	74	66
Additional paid-in-capital	736,339	684,413
Accumulated other comprehensive income	9	14
Accumulated deficit	-681,473	-615,313
Total stockholders' equity	54,949	69,180
Total liabilities and stockholders' equity	$124,523	$136,185

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Consolidated Balance Sheets [Abstract]
Preferred Stock, par value	$0.00	$0.00
Preferred Stock, shares authorized	50,000,000	50,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$0.00	$0.00
Common Stock, shares authorized	1,000,000,000	1,000,000,000
Common Stock, shares issued	73,927,000	66,275,000
Common Stock, shares outstanding	73,927,000	66,275,000

Consolidated_Statements_Of_Ope

Consolidated Statements Of Operations And Comprehensive Loss (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenue:
Product revenue	$35,299	$20,039	$20,089
Service and other revenue	8,511	6,446	5,894
Contractual revenue	16,784	1,696
Total revenue	60,594	28,181	25,983
Cost of Revenue:
Cost of product revenue	29,626	15,706	18,796
Cost of service and other revenue	7,566	6,056	6,247
Total cost of revenue	37,192	21,762	25,043
Gross profit	23,402	6,419	940
Operating Expense:
Research and development	48,230	45,217	47,623
Sales, general and administrative	38,026	38,745	47,655
Total operating expense	86,256	83,962	95,278
Operating loss	-62,854	-77,543	-94,338
Interest expense	-2,828	-2,478	-274
Other income (expense), net	-478	728	147
Net loss	-66,160	-79,293	-94,465
Other comprehensive loss:
Unrealized loss on investments	-5	-16	-27
Comprehensive loss	($66,165)	($79,309)	($94,492)
Net loss per share:
Basic and diluted net loss per share	($0.94)	($1.26)	($1.69)
Shares used in computing basic and diluted net loss per share	70,475	62,784	55,733

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Total
In Thousands
Balance at Dec. 31, 2011	$55	$632,906	$57	($441,555)	$191,463
Balance, shares at Dec. 31, 2011	54,964
Net loss				-94,465	-94,465
Other comprehensive loss			-27		-27
Issuance of common stock in conjunction with equity plans	1	2,704			2,705
Issuance of common stock in conjunction with equity plans, shares	1,206
Stock-based compensation expense		9,706			9,706
Balance at Dec. 31, 2012	56	645,316	30	-536,020	109,382
Balance, shares at Dec. 31, 2012	56,170
Net loss				-79,293	-79,293
Other comprehensive loss			-16		-16
Issuance of common stock in conjunction with equity plans	2	3,077			3,079
Issuance of common stock in conjunction with equity plans, shares	1,795
Issuance of common stock in conjunction with at-the-market equity offering, net of issuance costs	8	19,919			19,927
Issuance of common stock in conjunction with at-the-market equity offering, net of issuance costs, shares	8,310
Issuance of warrants in conjunction with debt facility, net of issuance costs		6,196			6,196
Stock-based compensation expense		9,905			9,905
Balance at Dec. 31, 2013	66	684,413	14	-615,313	69,180
Balance, shares at Dec. 31, 2013	66,275				66,275
Net loss				-66,160	-66,160
Other comprehensive loss			-5		-5
Issuance of common stock in conjunction with equity plans	2	3,966			3,968
Issuance of common stock in conjunction with equity plans, shares	1,901
Issuance of common stock in conjunction with at-the-market equity offering, net of issuance costs	6	38,017			38,023
Issuance of common stock in conjunction with at-the-market equity offering, net of issuance costs, shares	5,751
Stock-based compensation expense		9,943			9,943
Balance at Dec. 31, 2014	$74	$736,339	$9	($681,473)	$54,949
Balance, shares at Dec. 31, 2014	73,927				73,927

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities
Net loss	($66,160)	($79,293)	($94,465)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	4,221	5,648	6,649
Amortization of debt discount and financing costs	793	595
Stock-based compensation	9,943	9,905	9,705
Other items	507	-352	1,295
Changes in assets and liabilities
Accounts receivable	-660	76	1,735
Inventory	-1,285	-60	4,761
Prepaid expenses and other assets	-224	840	50
Accounts payable	3,891	-1,271	-1,754
Accrued expenses	3,536	1,327	-1,333
Deferred service revenue	2,686	386	-1,674
Deferred contractual revenue	-6,784	33,304
Other liabilities	-1,932	-938	-1,791
Net cash used in operating activities	-51,468	-29,833	-76,822
Cash flows from investing activities
Purchase of property and equipment	-1,609	-909	-1,703
Purchase of investments	-126,413	-201,547	-87,889
Sales of investments		100	7,896
Maturities of investments	147,586	169,239	143,488
Net cash provided by (used in) investing activities	19,564	-33,117	61,792
Cash flows from financing activities
Proceeds from issuance of common stock from equity plans	3,968	3,079	2,705
Proceeds from issuance of common stock from at-the-market equity offering, net of issuance costs	38,023	19,927
Proceeds from issuance of debt agreement, net of issuance costs		19,766
Net cash provided by financing activities	41,991	42,772	2,705
Net increase (decrease) in cash and cash equivalents	10,087	-20,178	-12,325
Cash and cash equivalents at beginning of period	26,362	46,540	58,865
Cash and cash equivalents at end of period	36,449	26,362	46,540
Supplemental disclosure of cash flow information
Interest paid	1,794	1,165
Supplemental disclosure of non-cash investing and financing activities
Inventory transferred to (from) property and equipment internal use		($558)	$1,164

Overview

Overview	12 Months Ended
	Dec. 31, 2014
Overview [Abstract]
Overview	NOTE 1.  OVERIEW
	Pacific Biosciences of California, Inc., (“Pacific Biosciences”, the “Company”, “we”, “us”) has commercialized the PacBio RS II High Resolution Genetic Analyzer to help scientists solve genetically complex problems. Based on our novel Single Molecule, Real-Time (SMRT®) technology, our products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. Our technology combines very high consensus accuracy and long read lengths with the ability to detect real-time kinetic information.
	The names “Pacific Biosciences,” “PacBio,” “SMRT,” “SMRTbell” and our logo are our trademarks.

Summary_Of_Significant_Account

Summary Of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation and Consolidation
	Our consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated. Translation adjustments resulting from translating foreign subsidiaries’ results of operations and assets and liabilities into U.S. dollars are immaterial for all periods presented.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying Notes to the Consolidated Financial Statements. Our estimates include, but are not limited to, the valuation of inventory, revenue valuation, the valuation of financing derivative and long-term notes, the valuation and recognition of share-based compensation, the valuation of warrants, the delivery period for collaboration agreements, the useful lives assigned to long-lived assets, and the computation provisions for income taxes. Actual results could differ materially from these estimates.
	Reclassifications
	Certain prior period amounts, as indicated below in details, have been reclassified to conform to current period presentation. Such reclassifications did not impact our financial position, net loss and cash flow.
		·		In the consolidated balance sheets as of December 31, 2013, we reclassified $1.9 million of “Accrued expenses and other current liabilities” to “Other liabilities, current”; and
		·		In the consolidated statements of cash flows for the years ended December 31, 2013 and 2012, we reclassified $66,000 and $1,008,000 from “Prepaid expenses and other assets” to the “Other items”, respectively.
	Fair Value of Financial Instruments
	The carrying amount of our financial assets and liabilities, including accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other current liabilities, approximate fair value due to their short maturities. The carrying value of our facility financing obligation approximates fair value based on the short duration to expected settlement, currently available borrowing rates and after consideration of non-performance risk and credit risk.
	The fair value hierarchy established under GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level input that is significant to the fair value measurement. The three levels of inputs that may be used to measure fair value are as follows:
		•		Level 1: quoted prices in active markets for identical assets or liabilities;
		•		Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
		•		Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis.  Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively.
	Our cash deposits and money market funds are classified within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. Our investments are classified as Level 2 instruments based on market pricing and other observable inputs. None of our investments are classified within Level 3 of the fair value hierarchy.
	Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability.
	Assets and liabilities measured at fair value on a recurring basis
	The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis as of December 31, 2014 and 2013, respectively (in thousands):
		December 31, 2014									December 31, 2013
	(in thousands)	Level 1			Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets
	Cash and cash equivalents:
	Cash and money market funds	$	21,952		$	—	$	—	$	21,952	$	12,963	$	—	$	—	$	12,963
	Commercial paper		—			14,497		—		14,497		—		13,399		—		13,399
	Total cash and cash equivalents		21,952			14,497		—		36,449		12,963		13,399		—		26,362
	Investments:
	Commercial paper		—			43,653		—		43,653		—		61,264		—		61,264
	Corporate debt securities		—			8,173		—		8,173		—		8,629		—		8,629
	Asset backed securities		—			13,073		—		13,073		—		16,273		—		16,273
	Total investments		—			64,899		—		64,899		—		86,166		—		86,166
	Total assets measured at fair value	$	21,952		$	79,396	$	—	$	101,348	$	12,963	$	99,565	$	—	$	112,528
	Liabilities
	Financing derivative	$	—		$	—	$	944	$	944	$	—	$	—	$	549	$	549
	Total liabilities measured at fair value	$	—		$	—	$	944	$	944	$	—	$	—	$	549	$	549
	The estimated fair value of the Financing Derivative liability (as defined in Note 6. Notes payable) was determined using Level 3 inputs, or significant unobservable inputs. Changes to the estimated fair value of the Financing Derivative are recorded in “Other income (expense), net” in the consolidated statements of operations and comprehensive loss.
	The following table provides the changes in the fair value of the Financial Derivative for the year ended December 31, 2014 and 2013 (in thousands), respectively.
	Financing Derivative		Amount
	Balance as of January 1, 2013		$	—
	Value at issuance			967
	Gain on change in fair value of Financing Derivative			-418
	Balance as of December 31, 2013			549
	Loss on change in fair value of Financing Derivative			395
	Balance as of December 31, 2014		$	944
	For the year ended December 31, 2014, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis and valuation techniques did not change compared to the prior year.
	Financial assets and liabilities not measured at fair value on a recurring basis
	The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other current liabilities approximate fair value due to their short maturities. The carrying value of our facility financing obligation approximates fair value due to the time to maturity and prevailing market rates.
	We determined the fair value of the Notes (as defined in Note 6. Notes payable) from the debt facility we entered into during the first quarter of 2013 using Level 3 inputs, or significant unobservable inputs.  The value of the Notes was determined by comparing the difference between the fair value of the Notes with and without the Financing Derivative by calculating the respective present values from future cash flows using a 19.5% and 20.4% weighted average market yield. Refer to Note 6. Notes payable for additional details regarding the Notes. The estimated fair value and carrying value of the Notes are as follows (in thousands):
		December 31, 2014					December 31, 2013
		Fair Value			Carrying Value		Fair Value		Carrying Value
	Long-term notes payable	$	14,817		$	14,124	$	14,551	$	13,347
	Cash and cash equivalents
	We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.
	Investments
	We have designated all investments as available-for-sale and therefore, such investments are reported at fair value, with unrealized gains and losses recognized in accumulated other comprehensive income (loss) (“OCI”) in stockholders’ equity. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is included in other income, net.  Realized gains and losses, as well as interest income, on available-for-sale securities are also included in other income, net. The cost of securities sold is based on the specific identification method. We include all of our available-for-sale securities in current assets.
	All of our investments are subject to a periodic impairment review. We recognize an impairment charge when a decline in the fair value of our investments below the cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the length of time and extent to which the investments fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, extent of the loss related to credit of the issuer, the expected cash flows from the security, our intent to sell the security and whether or not we will be required to sell the security before the recovery of its amortized cost. During the years ended December 31, 2014, 2013 and 2012, we did not recognize any impairment charges on our investments as it is more likely than not that we will recover their amortized cost basis upon sale or maturity.
	Concentration of Credit Risk
	The counterparties to the agreements relating to our investment securities consist of various major corporations, financial institutions, municipalities and government agencies of high credit standing. Our accounts receivable are derived from net revenue to customers and distributors located in the United States and other countries. We perform credit evaluations of our customers’ financial condition and, generally, require no collateral from our customers. We regularly review our accounts receivable including consideration of factors such as historical experience, credit quality, the age of the accounts receivable balances and current economic conditions that may affect a customer’s ability to pay. We have not experienced any significant credit losses to date.
	For the year ended December 31, 2014, contractual revenue from Roche accounted for more than 10% of our total revenue. For each of the years ended December 31, 2013 and 2012, no single end customer accounted for more than 10% of our total revenue. As of December 31, 2014 and 2013, 58% and 39%, respectively, of our accounts receivable were from domestic customers. As of December 31, 2014, three customers each represented more than 10% of our net accounts receivable. As of December 31, 2013, one customer represented 37% of our net accounts receivable. No other customer represented more than 10% of our net accounts receivable as of December 31, 2013.
	Inventory
	Inventory is valued at the lower of standard cost, which approximates actual cost, or market. Cost is determined using the FIFO (first-in, first-out) method. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess or obsolete balances.
	Property and Equipment, Net
	Property and equipment are stated at cost, net of accumulated depreciation and any impairment charges. Depreciation is computed using the straight-line method over the estimated useful life of the asset, generally two to three years for computer equipment, three to five years for software, three to seven years for furniture and fixtures, three years for lab equipment and 30 years for buildings. Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the related asset. Major improvements are capitalized, while maintenance and repairs are expensed as incurred.
In connection with build-to-suit lease arrangements that we account for as if we own the facility, we record the facility at the fair value at the date construction commences, prior to significant renovations, plus the costs of the renovations. We determined the fair value of such facilities prior to renovation based on several factors, including an appraisal conducted by an independent licensed appraiser.
Impairment of Long-Lived Assets
We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset is impaired or the estimated useful lives are no longer appropriate. Fair value is estimated based on discounted future cash flows. If indicators of impairment exist and the undiscounted projected cash flows associated with such assets are less than the carrying amount of the asset, an impairment loss is recorded to write the asset down to its estimated fair values. To date, we have not recorded any impairment charges.
Revenue Recognition
Our revenue is generated primarily from the sale of products and services, and collaboration agreements. Product revenue consists of sales of our instruments and related consumables; Service and other revenue primarily consist of revenue earned from product maintenance agreements and grant revenue. Contractual revenue relates to revenue recognized from the collaboration agreement under which we received an upfront fee and related revenue earned from the achievement of development milestones. Our deliverables under the arrangement includes licenses to intellectual property rights and research and development services.
We recognize revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. For instances where final acceptance of the product or system is required, revenue is deferred until all acceptance criteria have been met. Revenue for product sales is generally recognized upon customer acceptance. Revenue for product maintenance agreements is recognized when earned, which is generally ratably over the service period. In order to assess whether the price is fixed or determinable, we evaluate whether refund rights exist. If refund rights exist or payment terms are based on future performance, we defer revenue recognition until the price becomes fixed or determinable. We assess collectability based on a number of factors, including customer creditworthiness. If we determine that collection of amounts due is not reasonably assured, revenue recognition is deferred until receipt of payment.
We regularly enter into arrangements, comprised of one or more contracts, from which revenue is derived from multiple deliverables including a mix of products and or services. Revenue recognition for contracts with multiple deliverables is based on the individual units of accounting determined to exist in the contract. A delivered item is considered a separate unit of accounting when (i) the delivered item has value to the customer on a stand-alone basis; and (ii) if a general right of return exists, the delivery or performance of an undelivered item is considered probable and under our control. Items are considered to have stand-alone value when they are sold separately by any vendor or when the customer could resell the item on a stand-alone basis. Our revenue arrangements generally do not have a general right of return. When a deliverable does not meet the criteria to be considered a separate unit of accounting, we group it with other deliverables that, when combined, meet the criteria, and the appropriate allocation of arrangement consideration and revenue recognition is determined. Consideration is allocated at the inception of the contract to all deliverables based on their relative selling price. In order to determine the relative selling price of a deliverable, we apply, in order, vendor-specific objective evidence (“VSOE”); third-party evidence if VSOE is not available; and lastly our best estimate of selling price for the deliverable if neither VSOE nor third-party evidence is available.
In order to establish VSOE, we must regularly sell the product or service on a standalone basis with a substantial majority of sales priced within a relatively narrow range. If an insufficient number of standalone sales exist and VSOE cannot be determined, we then consider whether third party evidence can be used to establish selling price. Due to the lack of similar products and services sold by other companies within our industry, we have not established selling price using third-party evidence. If neither VSOE nor third party evidence of selling price exists, we determine our best estimate of selling price using a combination of prices set by our pricing committee adjusted for applicable discounts and customer orders received to date.
For our collaboration agreement, the process for determining estimates of selling prices of the identifiable deliverables involves significant judgments and estimates to be made by management. Our process considers multiple factors such as estimated headcount, annual research and development budget, estimated length of the research and development period and estimated transfer price on cost, which may vary over time, depending upon the circumstances, and are specific to each deliverable. If the estimated obligation period of one or more deliverables should change, the future amortization of the revenue would also change.
Deferred service revenue primarily represents product maintenance agreement revenue that is expected to be recognized over the related service period, generally one to three years.
Cost of Revenue
Cost of revenue reflects the direct cost of product components, third-party manufacturing services and our internal manufacturing overhead and customer service infrastructure costs incurred to produce, deliver, maintain and support our instruments, consumables, and services. There are no incremental costs associated with our contractual revenue; all product development costs are reflected in research and development expense.
Manufacturing overhead is predominantly comprised of labor costs. We determine and capitalize manufacturing overhead into inventory based on a standard cost model that approximates actual costs.  Prior to achieving manufacturing volumes that correlated with our estimated normal capacity (the production levels expected to be achieved over a number of periods under normal circumstances with available resources), we based our capitalized overhead relative to our normal capacity.  Prior to achieving normal capacity, excess manufacturing resources were engaged in research and development activities, including; next generation products, internal use research products, and general support activities. As such, manufacturing costs in excess of amounts reflected in inventory were expensed as a component of research and development expense. During 2014, manufacturing volumes trended towards and then approximated normal capacity, and excess manufacturing resources contributing to research and development activities declined significantly.
Service costs include the direct costs of components used in support, repair and maintenance of customer instruments as well as the cost of personnel, materials, shipping and support infrastructure necessary to support the installed customer base. Prior to the fourth quarter of 2013, the capacity of our existing service infrastructure exceeded the number of installed customer instruments. Therefore, management estimated the capacity of the existing service infrastructure and recognized the service-related cost of revenue based on the installed base. As a result, prior to the fourth quarter of 2013, total service infrastructure costs exceeded the costs associated with the support of customer instruments and such excess costs were included as a component of sales, general and administrative expense.
Research and Development
Research and development expense consists primarily of expenses for personnel engaged in the development of our SMRT technology, the design and development of our future products and current product enhancements. These expenses also include prototype-related expenditures, development equipment and supplies, facilities costs and other related overhead. We expense research and development costs during the period in which the costs are incurred. However, we defer and capitalize non-refundable advance payments made for research and development activities until the related goods are received or the related services are rendered.
Leases
We categorize leases at their inception as either operating or capital leases. On certain of our lease agreements, we may receive tenant improvement allowances, rent holidays and other incentives. Rent expense is recorded on a straight-line basis over the term of the lease. The difference between rent expense recognized and amounts paid under the lease agreement is recorded as deferred rent in the balance sheets. Leasehold improvements are capitalized at cost and depreciated over the shorter of their expected useful life or the life of the lease. Tenant improvements afforded to us by landlord incentives are recorded as leasehold improvement assets with corresponding deferred rent liabilities.
For build-to-suit lease arrangements, we evaluate the extent of our financial and operational involvement in the tenant improvements to determine whether we are considered the owner of the construction project under GAAP. When we are considered the owner of a project, we record the shell of the facility at its fair value at the date construction commences with a corresponding facility financing obligation. Improvements to the facility during the construction project are capitalized and, to the extent funded by lessor afforded incentives, with corresponding increases to the facility financing obligation. Payments we make under leases in which we are considered the owner of the facility are allocated to land rental expense, based on the relative values of the land and building at the commencement of construction, reductions of the facility financing obligation and interest expense recognized on the outstanding obligation. As the build-out was completed in 2010, the activity in 2014 consisted solely of lease payments. To the extent gross future payments do not equal the recorded liability, the liability is settled upon return of the facility to the lessor. Any difference between the book value of the assets and remaining facility obligation are recorded in other expense, net. For existing arrangements, the differences are expected to be immaterial.
Income Taxes
We account for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of our assets and liabilities and the amounts reported in the financial statements. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. A full valuation allowance is provided against our net deferred tax assets as it is more likely than not that the deferred tax assets will not be fully realized.
We review our positions taken relative to income taxes. To the extent our tax positions are more likely than not to result in the payout of additional taxes, we accrue the estimated amount of tax for such uncertain positions.
Stock-based Compensation
Stock-based compensation expense for all stock-based compensation awards is based on the grant date fair value estimated using the Black-Scholes option pricing model. We have limited historical information available to support the underlying estimates of certain assumptions required to value stock options. The expected term of options is estimated based on the simplified method. We do not have sufficient trading history to solely rely on the volatility of our own common stock for establishing expected volatility.  Therefore, we based our expected volatility on the historical stock volatilities of our common stock as well as several comparable publicly listed companies over a period equal to the expected term of the options. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for the expected term of the stock option.  We estimate our forfeiture rate based on an analysis of our actual forfeitures and will continue to evaluate the adequacy of the forfeiture rate based on actual forfeiture experience, analysis of employee turnover behavior and other factors. The impact from a forfeiture rate adjustment will be recognized in full in the period of adjustment, and if the actual number of future forfeitures differs from that estimated, we may be required to record adjustments to stock-based compensation expense in future periods.  We recognize compensation expense on a straight-line basis over the requisite service period. We elected to use the simplified method to calculate the beginning pool of excess tax benefits.
Other Comprehensive Income (loss)
Other comprehensive income (loss) is comprised of unrealized gains (losses) on our investment securities.
Recent Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers, requiring entities to recognize revenue to which they expect to be entitled to for the transfer of promised goods or services to customers.  The updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either a retrospective or cumulative effect transition method. The updated standard is effective for us beginning in the first quarter of fiscal year 2017 and early adoption is not permitted. We are evaluating the impact of adopting this ASU on our financial statements and related disclosures.
In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This ASU introduces an explicit requirement for management to assess if there is substantial doubt about an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. Disclosures are required if conditions give rise to substantial doubt. This ASU is effective for us for the year ending December 31, 2016.

Contractual_Revenue

Contractual Revenue	12 Months Ended
	Dec. 31, 2014
Contractual Revenue [Abstract]
Contractual Revenue	NOTE 3. CONTRACTUAL REVENUE
	During September 2013 we entered into a Development, Commercialization and License Agreement (the “Roche Agreement”) with F. Hoffman-La Roche Ltd (“Roche”), pursuant to which we account for, and recognize as revenue, the up-front payment using the proportional performance method over the periods in which the delivery of elements of the agreement occurs. We recognize revenue using a straight line convention over the service periods of the deliverables as this method approximates our performance of services pursuant to the contract. Out of the $35.0 million upfront cash payment received, $6.8 million and $1.7 million have been recognized as contractual revenue for the years ended December 31, 2014 and 2013, respectively, and $26.5 million remain deferred as of December 31, 2014 and will be recognized as contractual revenue over the estimated obligation periods. The amortization period is based upon management’s expectations of delivering pursuant to the Roche Agreement and is subject to change based on multiple factors including progress towards deliverables under the contract. Changes to management estimates could materially impact the amount of the upfront payment recognized into revenue during future periods.
	In addition to the deliverables above, the Roche Agreement provides for additional payments totaling up to $40.0 million upon the achievement of certain development milestones. Based on ASC Topic 605-28, Revenue Recognition — Milestone Method, we evaluate contingent milestones at inception of the agreement, and recognize consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is considered substantive in its entirety. Milestones are considered substantive if the consideration earned from the achievement of the milestone (i) is consistent with performance required to achieve the milestone or the increase in value to the delivered item, (ii) relates solely to past performance and (iii) is reasonable relative to all of the other deliverables and payments within the arrangement. During August 2014, we achieved the first development milestone and we recorded the related $10.0 million as contractual revenue. Under the terms of the Roche Agreement, we may receive up to an additional $30.0 million based on the achievement of additional development milestones in future periods.

Cash_Cash_Equivalents_And_Inve

Cash, Cash Equivalents And Investments	12 Months Ended
	Dec. 31, 2014
Cash, Cash Equivalents And Investments [Abstract]
Cash, Cash Equivalents And Investments
	NOTE 4.  CASH AND CASH EQUIVALENTS AND INVESTMENTS
	The following table summarizes our cash, cash equivalents and investments as of December 31, 2014 and December 31, 2013 (in thousands):
		As of December 31, 2014
				Gross		Gross
		Amortized		unrealized		unrealized		Fair
		Cost		gains		losses		Value
	Cash and cash equivalents:
	Cash and money market funds	$	21,952	$	—	$	—	$	21,952
	Commercial paper		14,496		1		—		14,497
	Total cash and cash equivalents		36,448		1		—		36,449
	Investments:
	Commercial paper		43,648		5		—		43,653
	Corporate debt securities		8,170		7		-4		8,173
	Asset backed securities		13,073		4		-4		13,073
	Total investments		64,891		16		-8		64,899
	Total cash, cash equivalents and investments	$	101,339	$	17	$	-8	$	101,348
		As of December 31, 2013
				Gross		Gross
		Amortized		unrealized		unrealized		Fair
		Cost		gains		losses		Value
	Cash and cash equivalents:
	Cash and money market funds	$	12,963	$	—	$	—	$	12,963
	Commercial paper		13,398		1		—		13,399
	Total cash and cash equivalents		26,361		1		—		26,362
	Investments:
	Commercial paper		61,252		13		-1		61,264
	Corporate debt securities		8,620		12		-3		8,629
	Asset backed securities		16,281		2		-10		16,273
	Total investments		86,153		27		-14		86,166
	Total cash, cash equivalents and investments	$	112,514	$	28	$	-14	$	112,528
	The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of December 31, 2014:
	(in thousands)	Fair Value
	Due in one year or less	$	78,113
	Due after one year through five years		1,283
	Total	$	79,396
	Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.

Balance_Sheet_Components

Balance Sheet Components	12 Months Ended
	Dec. 31, 2014
Balance Sheet Components [Abstract]
Balance Sheet Components
	NOTE 5.  BALANCE SHEET COMPONENTS
	Inventory:
	As of December 31, 2013 and 2012, our inventory consisted of the following components:
		December 31,
	(in thousands)	2014		2013
	Purchased materials	$	3,150	$	3,019
	Work in process		6,115		4,012
	Finished goods		2,070		3,019
	Inventory	$	11,335	$	10,050
	Property and Equipment, net:
	As of December 31, 2014 and 2013, our property and equipment, net, consisted of the following components:
		December 31,
	(in thousands)	2014		2013
	Building	$	1,160	$	1,160
	Laboratory equipment and machinery		17,169		16,934
	Leasehold improvements		8,348		8,111
	Computer equipment		4,885		3,885
	Software		4,485		4,457
	Furniture and fixtures		958		926
	Construction in progress		53		12
			37,058		35,485
	Less: Accumulated depreciation		-30,457		-26,249
	Property and equipment, net	$	6,601	$	9,236
	Depreciation expense during the years ended December 31, 2014, 2013 and 2012 was $4.2 million, $5.6 million and $6.6 million, respectively.
	Accrued expenses:
	As of December 31, 2014 and 2013, our accrued expenses consisted of the following:
		December 31,
	(in thousands)	2014		2013
	Salaries and benefits	$	6,325	$	5,149
	Accrued license and development services		3,741		1,328
	Inventory accrual, professional services, accrued interest and other		1,375		1,428
	Accrued expenses	$	11,441	$	7,905

Notes_Payable

Notes Payable	12 Months Ended
	Dec. 31, 2014
Notes Payable [Abstract]
Notes Payable
	NOTE 6. NOTES PAYABLE
	Pursuant to a Facility Agreement (the “Facility Agreement”) we entered into with entities affiliated with Deerfield Management Company, L.P. (collectively, “Deerfield”) during February 2013, we issued promissory notes in the aggregate principal amount of $20.5 million (the “Notes”). The Notes bear simple interest at a rate of 8.75% per annum, payable quarterly in arrears commencing on April 1, 2013. In connection with the execution of the Facility Agreement, we issued warrants to purchase an aggregate of 5,500,000 shares of common stock immediately exercisable at an exercise price per share initially equal to $2.63 (the “Warrants”). In addition, we are required to maintain consolidated cash and cash equivalents on the last day of each calendar quarter of not less than $2.0 million. As security for our repayment of our obligations under the Facility Agreement, we granted to Deerfield a security interest in substantially all of our property.
	Financing Derivative
	A number of features embedded in the Notes to the Facility Agreement required accounting for as a derivative, including the indemnification of certain withholding taxes and the acceleration of debt upon (i) a qualified financing, (ii) an Event of Default, (iii) a Major Transaction, and (iv) the exercise of the warrant via offset to debt principal. These features represent a single derivative (the “Financing Derivative”) that was bifurcated from the debt instrument and accounted for as a liability at fair value, with changes in fair value between reporting periods recorded in the other income (expense), net.
	The estimated fair value of the Financing Derivative was determined by comparing the difference between the fair value of the Notes with and without the Financing Derivative by calculating the respective present values from future cash flows using a  19.5% and 20.4% weighted average market yield, respectively at December 31, 2014 and December 31, 2013, respectively. The estimated fair value of the Financing Derivative as of December 31, 2014 and December 31, 2013, was $0.9 million and $0.5 million, respectively.
	Notes
	We initially recorded the Notes and Warrants at a value of $14.1 million and $6.4 million, respectively, based upon the relative fair value allocation of the $20.5 million of proceeds. The carrying value of the Notes at the inception of the debt was $12.8 million, resulting in an original issue discount of $7.7 million. As of December 31, 2014, $6.4 million remains to be amortized through February 2020, the maturity of the Notes.
	As of December 31, 2014, debt payments, which include interest and principal, are as follows (in thousands):
	2015	$	1,794
	2016		1,799
	2017		1,794
	2018		5,632
	Thereafter		17,959
	Total remaining payments		28,978
	Less: interest and discounts		-14,854
	Notes payable	$	14,124

Facility_Financing

Facility Financing	12 Months Ended
	Dec. 31, 2014
Facility Financing [Abstract]
Facility Financing	NOTE 7. FACILITY FINANCING
	In December 2009 we entered into a lease agreement for a manufacturing and office facility. In order for the facility to meet our needs and operating requirements, substantial tenant improvements, including improvements to the structural elements and principal operating systems of the facility, were necessary. The lessor provided a tenant improvement allowance of $1.8 million to apply towards the necessary improvements and we remained obligated for additional amounts over the afforded allowance.
	Due to our involvement in and the nature of the renovations made to the facility and our obligations to fund the costs of renovations exceeding the incentives afforded to us, we account for the facility as if we are the owner. Accordingly we recorded $3.0 million of building and leasehold improvement assets, reflecting the $1.2 million fair value of the facility prior to commencing renovations and the $1.8 million of landlord incentives within property and equipment, net and a corresponding liability recorded to facility financing obligation.
	As of December 31, 2014, the future minimum payments due under the facility financing obligation were as follows:
	(in thousands)	Financing obligation
	2015	$	668
	Less: interest and discounts		-416
	Total net payments under facility financing obligation		252
	Property reverting to landlord		2,151
	Present value of obligation		2,403
	Less: current portion of obligation		-252
	Long-term portion of obligation	$	2,151

Commitments_And_Contingencies

Commitments And Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments And Contingencies [Abstract]
Commitments And Contingencies	NOTE 8. COMMITMENTS AND CONTINGENCIES
	Operating Lease Commitment
	As of December 31, 2014, we have noncancelable operating lease agreements for research and development, office, manufacturing and training facilities in Menlo Park, California that expire in December 2015. Our leases have certain options to renew at rates approximating the prevailing fair market rental rate at the end of the lease term.
	As of December 31, 2014, the future annual minimum lease payments under all noncancelable operating leases with remaining term in excess of one year are as follows:
		Amount
	Years ending December 31,	(in thousands)
	2015	$	3,984
	2016		95
	Total minimum lease payments	$	4,079
	Rent expense for the years ended December 31, 2014, 2013 and 2012, was $2.2 million, $2.3 million and $2.4 million, respectively. We are also required to pay our share of operating expenses with respect to the facilities in which we operate.
	Other commitments include an estimated amount of approximately $13.6 million of all open cancellable purchase orders and contractual obligations that occur in the ordinary course of business, including commitments with suppliers, for which we have not received the goods or services.
	Contingencies
	We become subject to claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.
	We may, from time to time, be party to litigation and subject to claims that arise in the ordinary course of business. In addition, third parties may, from time to time, assert claims against us in the form of letters and other communications. We currently believe that these ordinary course matters will not have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
	Indemnification
	Pursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgments, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law.  In addition, we may have obligations to hold harmless and indemnify third parties involved with our fund raising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in connection with such fund raising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification obligations has been recorded at December 31, 2014.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Taxes [Abstract]
Income Taxes	NOTE 9. INCOME TAXES
	A reconciliation between the statutory federal income tax and our effective tax rates as a percentage of loss before income taxes are as follows:
		Years ended December 31,
		2014		2013		2012
	Statutory tax rate	35.0	%	35.0	%	35.0	%
	State tax rate, net of federal benefit	3.8		2.1		3.9
	Stock-based compensation	-1.3		-1.7		-1.7
	R&D credit	4.0		4.3		1.1
	Other	0		-0.3		-2.1
	Change in valuation allowance	-41.5		-39.4		-36.2
	Effective income tax rate	0.0	%	0.0	%	0.0	%
	Temporary differences and carryforwards that gave rise to significant portions of deferred taxes are as follows (in thousands):
		December 31,
	Deferred tax assets:	2014		2013
	Net operating loss carryforwards	$	225,115	$	214,312
	Research and development credits		24,881		22,263
	Depreciation		3,241		3,067
	Accruals and reserves		21,737		7,390
	Total deferred tax assets		274,974		247,032
	Less: Valuation allowance		-273,567		-246,186
	Deferred tax liabilities:
	Deferred rent		-1,407		-846
	Net deferred tax assets	$	—	$	—
	Due to uncertainties surrounding the realization of deferred tax assets through future taxable income, we have provided a full valuation allowance and, therefore, have not recognized any benefits from net operating losses and other deferred tax assets.
	Recognition of deferred tax assets is appropriate when realization of such assets is more likely than not. Based upon the weight of available evidence, we believe it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, we have provided a full valuation allowance against our net deferred tax assets as of December 31, 2014 and 2013, respectively.
	For the year ended December 31, 2014, our valuation allowance increased $27.4 million primarily because of an increase in deferred tax assets related to net operating losses, state tax credits, and changes in accruals and reserves. For the year ended December 31, 2013, our valuation allowance increased $31.9 million primarily because of an increase in deferred tax assets related to net operating losses, state research and development tax credits, and changes in accruals and reserves. As of December 31, 2014, we had federal and state net operating loss carryforwards of approximately $579.7 million and $526.6 million, respectively, available to reduce future taxable income, if any. The federal net operating loss carryforward begins expiring in 2024, and the state net operating loss carryforward began expiring in 2014.
	We also had federal and California state research and development credit carryforwards of approximately $21.0 million and $22.3 million, respectively, as of December 31, 2014. The federal research and development credits begin expiring in 2024 if not utilized. The California tax research and development credits can be carried forward indefinitely.
	Tax attributes related to stock option windfall deductions are not recorded until they result in a reduction of cash tax payable. The tax effected benefit of the excess tax deductions of the federal and state of $4.1 million and $0.6 million, respectively, will be recorded to additional paid-in capital when they reduce cash tax payable.
	The Tax Reform Act of 1986 limits the use of net operating loss and tax credit carryforwards in certain situations where equity transactions result in a change of ownership as defined by Internal Revenue Code Section 382. In the event we experience an additional ownership change for tax purposes, utilization of our United States net operating loss and tax credit carryforwards could be limited.
	As of December 31, 2014, our total unrecognized tax benefit was $17.0 million, of which none of the tax benefit, if recognized, would affect the effective income tax rate due to the valuation allowance that currently offsets deferred tax assets. We do not anticipate the total amount of unrecognized income tax benefits to significantly increase or decrease in the next 12 months.
	A reconciliation of the beginning and ending unrecognized tax benefit accounts is as follows (in thousands):
	Balance as of December 31, 2011	$	9,287
	Increase in balance related to tax positions taken during current year		705
	Balance as of December 31, 2012		9,992
	Increase in balance related to tax positions taken during current year		1,642
	Balance as of December 31, 2013		11,634
	Increase in balance related to tax positions taken in prior year		2,959
	Increase in balance related to tax positions taken during current year		2,359
	Balance as of December 31, 2014	$	16,952
	Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December 31, 2014 and 2013, we had no accrued interest or penalties due to our net operating losses available to offset any tax adjustment. We file U.S. federal and various state income tax returns. For U.S. federal and state income tax purposes, the statute of limitations currently remains open for the years ending December 31, 2010 to present and December 31, 2009 to present, respectively. In addition, all of the net operating losses and research and development credit carryforwards that may be utilized in future years may be subject to examination. We are not currently under examination by income tax authorities in any jurisdiction.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity [Abstract]
Stockholders' Equity	NOTE 10. STOCKHOLDERS’ EQUITY
	Preferred Stock
	Our Certificate of Incorporation, as amended and restated in October 2010 in connection with the closing of our initial public offering, authorizes us to issue 1,000,000,000 shares of $0.001 par value common stock and 50,000,000 shares of $0.001 par value preferred stock. As of December 31, 2014 and 2013, there were no shares of preferred stock issued or outstanding.
	Common Stock
	Common stockholders are entitled to dividends when and if declared by our board of directors. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote.
	During 2012, we established an at-the-market offering, pursuant to which we may offer and sell, from time to time, shares of our common stock having an aggregate offering price of up to $30.0 million. During 2013, we established a second at-the-market offering to raise an additional $30.0 million. We will pay a commission equal to 3% of the gross proceeds from the sale of shares of our common stock under the offering. We are not obligated to make any sales of shares of our common stock under either offering. In the year ended December 31, 2014, we issued 5.8 million shares of our common stock at an average price of $6.81 per share through our “at-the-market” offering.
	On February 3, 2015, the sales agreement was amended again to increase the aggregate offering price for shares of our common stock by an additional $30.0 million.
	Warrants
	In connection with the execution of the Facility Agreement, we issued immediately exercisable warrants to purchase 5,500,000 shares of common stock at an exercise price per share initially equal to $2.63.  The number of shares of common stock into which the warrants are exercisable and the exercise price will be adjusted to reflect any stock splits, payment of stock dividends, recapitalizations, reclassifications or other similar adjustments in the number of outstanding shares of common stock. The exercise price may also be adjusted to reflect certain dividends or other distributions, including distributions of stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement or similar transaction. As of December 31, 2014, we had outstanding exercisable warrants to purchase an aggregate of 5,500,000 shares of common stock at $2.63 per share.
	Equity Plans
	As of December 31, 2014, we had three active equity plans, the 2010 Equity Incentive Plan, or “2010 Plan”, the 2010 Outside Director Equity Incentive Plan, or “2010 Director Plan”, and the 2010 Employee Stock Purchase Plan or “ESPP”, all of which we adopted upon the effectiveness of our initial public offering during October 2010. Prior to the adoption of these plans, we granted options pursuant to the 2004 Equity Incentive Plan and 2005 Stock Plan.  Upon termination of the predecessor plans, the shares available for grant at the time of termination, and shares subsequently returned to the plans upon forfeiture or option termination, were transferred to the successor plan in effect at the time of share return.
	We issue new shares of common stock upon exercise of stock options.
	2010 Equity Incentive Plan and Outside Director Equity Incentive Plan
	Stock options granted under the 2010 Plan may be either ISOs or NSOs. ISOs may be granted only to employees. NSOs may be granted to employees, consultants and directors. Stock options under the 2010 Plan may be granted with a term of up to ten years and at prices no less than the fair market value of our common stock on the date of grant. To date, stock options granted to existing employees generally vest over four years on a monthly basis and stock options granted to new employees vest at a rate of 25% upon the first anniversary of the vesting commencement date and 1/48th per month thereafter. In January 2015, an additional 3.7 million shares were reserved under the 2010 Plan.
	Stock options granted under the 2010 Director Plan provide for the grant of NSOs. Stock options under the 2010 Plan may be granted with a term of up to ten years and at prices no less than the fair market value of our common stock on the date of grant. To date, stock options granted to existing directors generally vest over one year on a monthly basis and stock options granted to new directors generally vest over three years at a rate of one-third upon the first anniversary of the vesting commencement date and 1/36th per month thereafter. In January 2015, an additional 0.7 million shares were reserved under the 2010 Director Plan.
	As of December 31, 2014 we reserved an aggregate of 4.9 million shares of common stock for future issuance under the 2010 Plan and 2010 Director Plan.
	2010 Employee Stock Purchase Plan
	We adopted the ESPP in October 2010. Our ESPP permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. Each offering period will generally consist of four purchase periods, each purchase period being approximately six months. The price at which the stock is purchased is equal to the lower of 85% of the fair market value of the common stock at the beginning of an offering period or at the end of a purchase period. Each offering period will generally end and the shares will be purchased twice yearly on March 1 and September 1. As of December 31, 2014,  no shares of our common stock remain available for issuance under the Plan; however the ESPP provides for an annual increase to the shares available for issuance at the beginning of each calendar year equal to 2% of the common shares then outstanding. During January 2015, an additional 1.5 million shares were reserved under the ESPP.
	The following table summarizes stock option activity for all stock option plans for the year ended December 31, 2014 (in thousands, except per share amounts):
				Stock Options Outstanding
		Shares available		Number					Weighted average
		for grant		of shares		Exercise price			exercise price
	Balances, December 31, 2013	3,912		14,070		$	0.20 – 16.00		$	4.81
	Additional shares reserved	3,977
	Options granted	-3,505		3,505		$	4.21 – 7.05		$	6.00
	Options exercised	—		-594		$	0.20 – 6.96		$	2.90
	Options canceled	490		-490		$	1.16 – 15.98		$	5.90
	Balances, December 31, 2014	4,874		16,491		$	0.70 – 16.00		$	5.10
	The following table summarizes information with respect to stock options outstanding and exercisable under the plans at December 31, 2014:
				Options Outstanding							Options Exercisable
						Weighted average
				Number		remaining contractual		Weighted average			Number	Weighted average
	Exercise price			outstanding		life (Years)		exercise price			vested	exercise price
	$	0.00 – 1.60		1,082,067		6.78		$	1.11		538,693	$	1.04
	$	1.60 – 3.20		4,071,281		6.94		$	2.40		2,489,111	$	2.43
	$	3.20 – 4.80		4,525,775		7.53		$	4.08		2,296,346	$	4.05
	$	4.80 – 6.40		2,459,863		8.74		$	5.62		578,535	$	5.72
	$	6.40 – 8.00		1,654,881		7.68		$	6.99		676,966	$	6.99
	$	8.00 – 9.60		1,125,101		5.04		$	8.50		1,125,101	$	8.50
	$	9.60 – 11.20		354,002		5.35		$	10.80		353,131	$	10.80
	$	11.20 – 12.80		687,610		6.00		$	12.11		560,578	$	12.17
	$	12.80 – 14.40		391,334		5.99		$	13.87		328,010	$	13.83
	$	14.40 – 16.00		139,250		5.87		$	15.99		138,500	$	15.99
				16,491,164		7.20		$	5.10		9,084,971	$	5.60
	The aggregate intrinsic value of the outstanding and exercisable options presented in the table above totaled $53.3 million and $27.6 million, respectively. The aggregate intrinsic value represents the total pretax intrinsic value (i.e., the difference between $7.84, our closing stock price on the last trading day of our fourth quarter of 2014 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2014. The amount changes based on the fair market value of our common stock. The weighted average remaining contractual life for exercisable options is 6.22 years.
	The total intrinsic value of options exercised during the years ended December 31, 2014, 2013 and 2012 was $2.0 million, $0.5 million and $0.7 million, respectively.
	The total fair value of options vested during the years ended December 31, 2014, 2013 and 2012 was $6.0 million, $6.5 million and $2.3 million, respectively.
	Stock-based Compensation
	Total stock-based compensation expense consists of the following (in thousands):
		Years Ended December 31,
		2014			2013			2012
	Cost of revenue	$	758		$	523		$	506
	Research and development		3,785			4,052			4,562
	Sales, general and administrative		5,400			5,330			4,637
	Total stock-based compensation expense	$	9,943		$	9,905		$	9,705
	The tax benefit of stock-based compensation expense was immaterial for the fiscal years ended December 31, 2014, 2013 and 2012.
	Stock options
	We estimated the fair value of employee stock option using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. For the years ended December 31, 2014, 2013 and 2012, weighted average fair value at grant date for stock option was $3.81,  $1.80 and $1.84 , respectively. We recorded stock-based compensation expense for stock options of $7.8 million, $7.0 million and $6.9 million for the years ended December 31, 2014, 2013 and 2012, respectively.
	For the years ended December 31, 2014, 2013 and 2012, the fair value of employee stock options was estimated using the following weighted average assumptions:
			Years Ended December 31,
			2014			2013			2012
	Expected term (years)			6.1 years			6.1 years			6.1 years
	Expected volatility			70.00%			66.80%			63.40%
	Risk-free interest rate			1.90%			1.30%			1.00%
Dividend yield			—			—			—
As of December 31, 2014, $15.4 million of total unrecognized compensation expense related to stock options was expected to be recognized over a weighted-average period of 2.8 years. Future option grants will increase the amount of compensation expense to be recorded in those future periods. Cash received from option exercises for the years ended December 31, 2014, 2013 and 2012 was $1.6 million, $0.5 million and $0.6 million, respectively.
ESPP
We estimated the fair value of ESPP using the Black-Scholes option pricing model. For the years ended December 31, 2014, 2013 and 2012, weighted average fair value at grant date for ESPP was $2.98,  $1.76 and $1.38, respectively. We recorded stock-based compensation expense for ESPP of $2.1 million, $2.8 million and $2.8 million for the years ended December 31, 2014, 2013 and 2012, respectively.
For the years ended December 31, 2014, 2013 and 2012, the fair value of ESPP was estimated using the following assumptions:
		Years Ended December 31,
		2014			2013			2012
Expected term (years)			0.5 - 2.0			0.5 - 2.0			0.5 - 2.0
Expected volatility			70.00%			70.00%			90.00%
Risk-free interest rate			0.1%-0.5%			0.1%-0.4%			0.1%-0.3%
Dividend yield			—			—			—
For the years ended December 31, 2014, 2013 and 2012, 1,325,507 shares, 1,519,366 shares and 832,878 shares of common stock were purchased under the Plan, respectively. Cash received from ESPP for the years ended December 31, 2014, 2013 and 2012 was $2.3 million, $2.6 million and $2.1 million, respectively.

Net_Loss_Per_Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2014
Net Loss Per Share [Abstract]
Net Loss Per Share	NOTE 11. NET LOSS PER SHARE
	The following table presents the computation of basic and diluted net loss per share (in thousands, except per share amounts):
		Years Ended December 31,
		2014			2013		2012
	Numerator:
	Net loss	$	-66,160		$	-79,293	$	-94,465
	Denominator:
	Weighted average shares used in computation of basic and diluted net loss per share		70,475			62,784		55,733
	Basic and diluted net loss per share	$	-0.94		$	-1.26	$	-1.69
	The following options outstanding and warrants to purchase common stock were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive in the periods presented:
		Years Ended December 31,
	(in thousands)	2014		2013		2012
	Options outstanding	16,491		14,070		12,016
	Warrants to purchase common stock	5,500		5,500		10

Segment_And_Geographic_Informa

Segment And Geographic Information	12 Months Ended
	Dec. 31, 2014
Segment And Geographic Information [Abstract]
Segment And Geographic Information	NOTE 12. SEGMENT AND GEOGRAPHIC INFORMATION
	We are organized as, and operate in, one reportable segment: the development, manufacturing and marketing of an integrated platform for genetic analysis. Our chief operating decision-maker is our Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis for purposes of evaluating financial performance and allocating resources, accompanied by information about revenue by geographic regions. Our assets are primarily located in the United States of America and not allocated to any specific region and we do not measure the performance of geographic regions based upon asset-based metrics. Therefore, geographic information is presented only for revenue. Revenue by geographic region is based on the ship to address on the customer order.
	A summary of our revenue by geographic location for the years ended December 31, 2014, 2013 and 2012 is as follows:
		Years Ended December 31,
	(in millions)	2014		2013		2012
	United States	$	34.8	$	13.6	$	11.4
	Europe		10.1		9.2		6.6
	Asia		15.7		5.4		8.0
	Total	$	60.6	$	28.2	$	26.0

Unaudited_Selected_Quarterly_F

Unaudited Selected Quarterly Financial Data	12 Months Ended
	Dec. 31, 2014
Unaudited Selected Quarterly Financial Data [Abstract]
Unaudited Selected Quarterly Financial Data	NOTE 13. UNAUDITED SELECTED QUARTERLY FINANCIAL DATA
	The following tables summarize the unaudited quarterly financial data for the last two fiscal years:
		Fiscal 2014 Quarter Ended
	(in thousands, except per share data)	March 31,			June 30,		September 30,			December 31,
	Total revenue	$	11,642		$	11,425	$	20,623		$	16,904
	Total gross profit		2,676			3,126		13,162	-1		4,438
	Total operating expenses		20,921			21,428		21,575			22,332
	Loss from operations		-18,245			-18,302		-8,413	-1		-17,894
	Net loss		-18,886			-19,136		-9,163			-18,975
	Basic and diluted net loss per share	$	-0.28		$	-0.27	$	-0.13		$	-0.26
		Fiscal 2013 Quarter Ended
		March 31,			June 30,		September 30,			December 31,
	Total revenue	$	5,578		$	6,048	$	7,421		$	9,134
	Total gross profit		930			1,059		1,241			3,189
	Total operating expenses		21,537			21,056		21,176			20,193
	Loss from operations		-20,607			-19,997		-19,935			-17,004
	Net loss		-21,104			-20,471		-20,487			-17,231
	Basic and diluted net loss per share	$	-0.37		$	-0.33	$	-0.31		$	-0.26
		-1		During the third quarter ended September 30, 2014, we achieved the first development milestone as provided in the Roche Agreement and we recorded the related $10.0 million as contractual revenue. See “Note 3. Contractual Revenue”  for additional information.

Summary_Of_Significant_Account1

Summary Of Significant Accounting Policies (Policy)	12 Months Ended
	Dec. 31, 2014
Summary Of Significant Accounting Policies [Abstract]
Basis Of Presentation	Basis of Presentation and Consolidation
	Our consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. All intercompany transactions and balances have been eliminated. Translation adjustments resulting from translating foreign subsidiaries’ results of operations and assets and liabilities into U.S. dollars are immaterial for all periods presented.
Use Of Estimates	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying Notes to the Consolidated Financial Statements. Our estimates include, but are not limited to, the valuation of inventory, revenue valuation, the valuation of financing derivative and long-term notes, the valuation and recognition of share-based compensation, the valuation of warrants, the delivery period for collaboration agreements, the useful lives assigned to long-lived assets, and the computation provisions for income taxes. Actual results could differ materially from these estimates.
Reclassifications	Reclassifications
	Certain prior period amounts, as indicated below in details, have been reclassified to conform to current period presentation. Such reclassifications did not impact our financial position, net loss and cash flow.
		·		In the consolidated balance sheets as of December 31, 2013, we reclassified $1.9 million of “Accrued expenses and other current liabilities” to “Other liabilities, current”; and
		·		In the consolidated statements of cash flows for the years ended December 31, 2013 and 2012, we reclassified $66,000 and $1,008,000 from “Prepaid expenses and other assets” to the “Other items”, respectively.
Fair Value Of Financial Instruments	Fair Value of Financial Instruments
	The carrying amount of our financial assets and liabilities, including accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other current liabilities, approximate fair value due to their short maturities. The carrying value of our facility financing obligation approximates fair value based on the short duration to expected settlement, currently available borrowing rates and after consideration of non-performance risk and credit risk.
	The fair value hierarchy established under GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level input that is significant to the fair value measurement. The three levels of inputs that may be used to measure fair value are as follows:
		•		Level 1: quoted prices in active markets for identical assets or liabilities;
		•		Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
		•		Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis.  Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively.
	Our cash deposits and money market funds are classified within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. Our investments are classified as Level 2 instruments based on market pricing and other observable inputs. None of our investments are classified within Level 3 of the fair value hierarchy.
	Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability.
	Assets and liabilities measured at fair value on a recurring basis
	The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis as of December 31, 2014 and 2013, respectively (in thousands):
		December 31, 2014									December 31, 2013
	(in thousands)	Level 1			Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets
	Cash and cash equivalents:
	Cash and money market funds	$	21,952		$	—	$	—	$	21,952	$	12,963	$	—	$	—	$	12,963
	Commercial paper		—			14,497		—		14,497		—		13,399		—		13,399
	Total cash and cash equivalents		21,952			14,497		—		36,449		12,963		13,399		—		26,362
	Investments:
	Commercial paper		—			43,653		—		43,653		—		61,264		—		61,264
	Corporate debt securities		—			8,173		—		8,173		—		8,629		—		8,629
	Asset backed securities		—			13,073		—		13,073		—		16,273		—		16,273
	Total investments		—			64,899		—		64,899		—		86,166		—		86,166
	Total assets measured at fair value	$	21,952		$	79,396	$	—	$	101,348	$	12,963	$	99,565	$	—	$	112,528
	Liabilities
	Financing derivative	$	—		$	—	$	944	$	944	$	—	$	—	$	549	$	549
	Total liabilities measured at fair value	$	—		$	—	$	944	$	944	$	—	$	—	$	549	$	549
	The estimated fair value of the Financing Derivative liability (as defined in Note 6. Notes payable) was determined using Level 3 inputs, or significant unobservable inputs. Changes to the estimated fair value of the Financing Derivative are recorded in “Other income (expense), net” in the consolidated statements of operations and comprehensive loss.
	The following table provides the changes in the fair value of the Financial Derivative for the year ended December 31, 2014 and 2013 (in thousands), respectively.
	Financing Derivative		Amount
	Balance as of January 1, 2013		$	—
	Value at issuance			967
	Gain on change in fair value of Financing Derivative			-418
	Balance as of December 31, 2013			549
	Loss on change in fair value of Financing Derivative			395
	Balance as of December 31, 2014		$	944
	For the year ended December 31, 2014, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis and valuation techniques did not change compared to the prior year.
	Financial assets and liabilities not measured at fair value on a recurring basis
	The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other current liabilities approximate fair value due to their short maturities. The carrying value of our facility financing obligation approximates fair value due to the time to maturity and prevailing market rates.
	We determined the fair value of the Notes (as defined in Note 6. Notes payable) from the debt facility we entered into during the first quarter of 2013 using Level 3 inputs, or significant unobservable inputs.  The value of the Notes was determined by comparing the difference between the fair value of the Notes with and without the Financing Derivative by calculating the respective present values from future cash flows using a 19.5% and 20.4% weighted average market yield. Refer to Note 6. Notes payable for additional details regarding the Notes. The estimated fair value and carrying value of the Notes are as follows (in thousands):
		December 31, 2014					December 31, 2013
		Fair Value			Carrying Value		Fair Value		Carrying Value
	Long-term notes payable	$	14,817		$	14,124	$	14,551	$	13,347
Cash And Cash Equivalents	Cash and cash equivalents
	We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.
Investments	Investments
	We have designated all investments as available-for-sale and therefore, such investments are reported at fair value, with unrealized gains and losses recognized in accumulated other comprehensive income (loss) (“OCI”) in stockholders’ equity. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is included in other income, net.  Realized gains and losses, as well as interest income, on available-for-sale securities are also included in other income, net. The cost of securities sold is based on the specific identification method. We include all of our available-for-sale securities in current assets.
	All of our investments are subject to a periodic impairment review. We recognize an impairment charge when a decline in the fair value of our investments below the cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the length of time and extent to which the investments fair value has been less than the cost basis, the financial condition and near-term prospects of the investee, extent of the loss related to credit of the issuer, the expected cash flows from the security, our intent to sell the security and whether or not we will be required to sell the security before the recovery of its amortized cost. During the years ended December 31, 2014, 2013 and 2012, we did not recognize any impairment charges on our investments as it is more likely than not that we will recover their amortized cost basis upon sale or maturity.
Concentration Of Credit Risk
	Concentration of Credit Risk
	The counterparties to the agreements relating to our investment securities consist of various major corporations, financial institutions, municipalities and government agencies of high credit standing. Our accounts receivable are derived from net revenue to customers and distributors located in the United States and other countries. We perform credit evaluations of our customers’ financial condition and, generally, require no collateral from our customers. We regularly review our accounts receivable including consideration of factors such as historical experience, credit quality, the age of the accounts receivable balances and current economic conditions that may affect a customer’s ability to pay. We have not experienced any significant credit losses to date.
	For the year ended December 31, 2014, contractual revenue from Roche accounted for more than 10% of our total revenue. For each of the years ended December 31, 2013 and 2012, no single end customer accounted for more than 10% of our total revenue. As of December 31, 2014 and 2013, 58% and 39%, respectively, of our accounts receivable were from domestic customers. As of December 31, 2014, three customers each represented more than 10% of our net accounts receivable. As of December 31, 2013, one customer represented 37% of our net accounts receivable. No other customer represented more than 10% of our net accounts receivable as of December 31, 2013.
Inventory	Inventory
	Inventory is valued at the lower of standard cost, which approximates actual cost, or market. Cost is determined using the FIFO (first-in, first-out) method. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess or obsolete balances.
Property And Equipment, Net	Property and Equipment, Net
	Property and equipment are stated at cost, net of accumulated depreciation and any impairment charges. Depreciation is computed using the straight-line method over the estimated useful life of the asset, generally two to three years for computer equipment, three to five years for software, three to seven years for furniture and fixtures, three years for lab equipment and 30 years for buildings. Leasehold improvements are depreciated over the shorter of the lease term or the estimated useful life of the related asset. Major improvements are capitalized, while maintenance and repairs are expensed as incurred.
	In connection with build-to-suit lease arrangements that we account for as if we own the facility, we record the facility at the fair value at the date construction commences, prior to significant renovations, plus the costs of the renovations. We determined the fair value of such facilities prior to renovation based on several factors, including an appraisal conducted by an independent licensed appraiser.
Impairment Of Long-Lived Assets	Impairment of Long-Lived Assets
	We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset is impaired or the estimated useful lives are no longer appropriate. Fair value is estimated based on discounted future cash flows. If indicators of impairment exist and the undiscounted projected cash flows associated with such assets are less than the carrying amount of the asset, an impairment loss is recorded to write the asset down to its estimated fair values. To date, we have not recorded any impairment charges.
Revenue Recognition	Revenue Recognition
	Our revenue is generated primarily from the sale of products and services, and collaboration agreements. Product revenue consists of sales of our instruments and related consumables; Service and other revenue primarily consist of revenue earned from product maintenance agreements and grant revenue. Contractual revenue relates to revenue recognized from the collaboration agreement under which we received an upfront fee and related revenue earned from the achievement of development milestones. Our deliverables under the arrangement includes licenses to intellectual property rights and research and development services.
	We recognize revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. For instances where final acceptance of the product or system is required, revenue is deferred until all acceptance criteria have been met. Revenue for product sales is generally recognized upon customer acceptance. Revenue for product maintenance agreements is recognized when earned, which is generally ratably over the service period. In order to assess whether the price is fixed or determinable, we evaluate whether refund rights exist. If refund rights exist or payment terms are based on future performance, we defer revenue recognition until the price becomes fixed or determinable. We assess collectability based on a number of factors, including customer creditworthiness. If we determine that collection of amounts due is not reasonably assured, revenue recognition is deferred until receipt of payment.
	We regularly enter into arrangements, comprised of one or more contracts, from which revenue is derived from multiple deliverables including a mix of products and or services. Revenue recognition for contracts with multiple deliverables is based on the individual units of accounting determined to exist in the contract. A delivered item is considered a separate unit of accounting when (i) the delivered item has value to the customer on a stand-alone basis; and (ii) if a general right of return exists, the delivery or performance of an undelivered item is considered probable and under our control. Items are considered to have stand-alone value when they are sold separately by any vendor or when the customer could resell the item on a stand-alone basis. Our revenue arrangements generally do not have a general right of return. When a deliverable does not meet the criteria to be considered a separate unit of accounting, we group it with other deliverables that, when combined, meet the criteria, and the appropriate allocation of arrangement consideration and revenue recognition is determined. Consideration is allocated at the inception of the contract to all deliverables based on their relative selling price. In order to determine the relative selling price of a deliverable, we apply, in order, vendor-specific objective evidence (“VSOE”); third-party evidence if VSOE is not available; and lastly our best estimate of selling price for the deliverable if neither VSOE nor third-party evidence is available.
	In order to establish VSOE, we must regularly sell the product or service on a standalone basis with a substantial majority of sales priced within a relatively narrow range. If an insufficient number of standalone sales exist and VSOE cannot be determined, we then consider whether third party evidence can be used to establish selling price. Due to the lack of similar products and services sold by other companies within our industry, we have not established selling price using third-party evidence. If neither VSOE nor third party evidence of selling price exists, we determine our best estimate of selling price using a combination of prices set by our pricing committee adjusted for applicable discounts and customer orders received to date.
	For our collaboration agreement, the process for determining estimates of selling prices of the identifiable deliverables involves significant judgments and estimates to be made by management. Our process considers multiple factors such as estimated headcount, annual research and development budget, estimated length of the research and development period and estimated transfer price on cost, which may vary over time, depending upon the circumstances, and are specific to each deliverable. If the estimated obligation period of one or more deliverables should change, the future amortization of the revenue would also change.
	Deferred service revenue primarily represents product maintenance agreement revenue that is expected to be recognized over the related service period, generally one to three years.
Cost Of Revenue	Cost of Revenue
	Cost of revenue reflects the direct cost of product components, third-party manufacturing services and our internal manufacturing overhead and customer service infrastructure costs incurred to produce, deliver, maintain and support our instruments, consumables, and services. There are no incremental costs associated with our contractual revenue; all product development costs are reflected in research and development expense.
	Manufacturing overhead is predominantly comprised of labor costs. We determine and capitalize manufacturing overhead into inventory based on a standard cost model that approximates actual costs.  Prior to achieving manufacturing volumes that correlated with our estimated normal capacity (the production levels expected to be achieved over a number of periods under normal circumstances with available resources), we based our capitalized overhead relative to our normal capacity.  Prior to achieving normal capacity, excess manufacturing resources were engaged in research and development activities, including; next generation products, internal use research products, and general support activities. As such, manufacturing costs in excess of amounts reflected in inventory were expensed as a component of research and development expense. During 2014, manufacturing volumes trended towards and then approximated normal capacity, and excess manufacturing resources contributing to research and development activities declined significantly.
	Service costs include the direct costs of components used in support, repair and maintenance of customer instruments as well as the cost of personnel, materials, shipping and support infrastructure necessary to support the installed customer base. Prior to the fourth quarter of 2013, the capacity of our existing service infrastructure exceeded the number of installed customer instruments. Therefore, management estimated the capacity of the existing service infrastructure and recognized the service-related cost of revenue based on the installed base. As a result, prior to the fourth quarter of 2013, total service infrastructure costs exceeded the costs associated with the support of customer instruments and such excess costs were included as a component of sales, general and administrative expense.
Research And Development	Research and Development
	Research and development expense consists primarily of expenses for personnel engaged in the development of our SMRT technology, the design and development of our future products and current product enhancements. These expenses also include prototype-related expenditures, development equipment and supplies, facilities costs and other related overhead. We expense research and development costs during the period in which the costs are incurred. However, we defer and capitalize non-refundable advance payments made for research and development activities until the related goods are received or the related services are rendered.
Leases	Leases
	We categorize leases at their inception as either operating or capital leases. On certain of our lease agreements, we may receive tenant improvement allowances, rent holidays and other incentives. Rent expense is recorded on a straight-line basis over the term of the lease. The difference between rent expense recognized and amounts paid under the lease agreement is recorded as deferred rent in the balance sheets. Leasehold improvements are capitalized at cost and depreciated over the shorter of their expected useful life or the life of the lease. Tenant improvements afforded to us by landlord incentives are recorded as leasehold improvement assets with corresponding deferred rent liabilities.
	For build-to-suit lease arrangements, we evaluate the extent of our financial and operational involvement in the tenant improvements to determine whether we are considered the owner of the construction project under GAAP. When we are considered the owner of a project, we record the shell of the facility at its fair value at the date construction commences with a corresponding facility financing obligation. Improvements to the facility during the construction project are capitalized and, to the extent funded by lessor afforded incentives, with corresponding increases to the facility financing obligation. Payments we make under leases in which we are considered the owner of the facility are allocated to land rental expense, based on the relative values of the land and building at the commencement of construction, reductions of the facility financing obligation and interest expense recognized on the outstanding obligation. As the build-out was completed in 2010, the activity in 2014 consisted solely of lease payments. To the extent gross future payments do not equal the recorded liability, the liability is settled upon return of the facility to the lessor. Any difference between the book value of the assets and remaining facility obligation are recorded in other expense, net. For existing arrangements, the differences are expected to be immaterial.
Income Taxes	Income Taxes
	We account for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of our assets and liabilities and the amounts reported in the financial statements. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. A full valuation allowance is provided against our net deferred tax assets as it is more likely than not that the deferred tax assets will not be fully realized.
	We review our positions taken relative to income taxes. To the extent our tax positions are more likely than not to result in the payout of additional taxes, we accrue the estimated amount of tax for such uncertain positions.
Stock-Based Compensation	Stock-based Compensation
	Stock-based compensation expense for all stock-based compensation awards is based on the grant date fair value estimated using the Black-Scholes option pricing model. We have limited historical information available to support the underlying estimates of certain assumptions required to value stock options. The expected term of options is estimated based on the simplified method. We do not have sufficient trading history to solely rely on the volatility of our own common stock for establishing expected volatility.  Therefore, we based our expected volatility on the historical stock volatilities of our common stock as well as several comparable publicly listed companies over a period equal to the expected term of the options. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for the expected term of the stock option.  We estimate our forfeiture rate based on an analysis of our actual forfeitures and will continue to evaluate the adequacy of the forfeiture rate based on actual forfeiture experience, analysis of employee turnover behavior and other factors. The impact from a forfeiture rate adjustment will be recognized in full in the period of adjustment, and if the actual number of future forfeitures differs from that estimated, we may be required to record adjustments to stock-based compensation expense in future periods.  We recognize compensation expense on a straight-line basis over the requisite service period. We elected to use the simplified method to calculate the beginning pool of excess tax benefits.
Other Comprehensive Income (Loss)	Other Comprehensive Income (loss)
	Other comprehensive income (loss) is comprised of unrealized gains (losses) on our investment securities.

Contractual_Revenue_Policy

Contractual Revenue (Policy)	12 Months Ended
	Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue Recognition	Revenue Recognition
	Our revenue is generated primarily from the sale of products and services, and collaboration agreements. Product revenue consists of sales of our instruments and related consumables; Service and other revenue primarily consist of revenue earned from product maintenance agreements and grant revenue. Contractual revenue relates to revenue recognized from the collaboration agreement under which we received an upfront fee and related revenue earned from the achievement of development milestones. Our deliverables under the arrangement includes licenses to intellectual property rights and research and development services.
	We recognize revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. For instances where final acceptance of the product or system is required, revenue is deferred until all acceptance criteria have been met. Revenue for product sales is generally recognized upon customer acceptance. Revenue for product maintenance agreements is recognized when earned, which is generally ratably over the service period. In order to assess whether the price is fixed or determinable, we evaluate whether refund rights exist. If refund rights exist or payment terms are based on future performance, we defer revenue recognition until the price becomes fixed or determinable. We assess collectability based on a number of factors, including customer creditworthiness. If we determine that collection of amounts due is not reasonably assured, revenue recognition is deferred until receipt of payment.
	We regularly enter into arrangements, comprised of one or more contracts, from which revenue is derived from multiple deliverables including a mix of products and or services. Revenue recognition for contracts with multiple deliverables is based on the individual units of accounting determined to exist in the contract. A delivered item is considered a separate unit of accounting when (i) the delivered item has value to the customer on a stand-alone basis; and (ii) if a general right of return exists, the delivery or performance of an undelivered item is considered probable and under our control. Items are considered to have stand-alone value when they are sold separately by any vendor or when the customer could resell the item on a stand-alone basis. Our revenue arrangements generally do not have a general right of return. When a deliverable does not meet the criteria to be considered a separate unit of accounting, we group it with other deliverables that, when combined, meet the criteria, and the appropriate allocation of arrangement consideration and revenue recognition is determined. Consideration is allocated at the inception of the contract to all deliverables based on their relative selling price. In order to determine the relative selling price of a deliverable, we apply, in order, vendor-specific objective evidence (“VSOE”); third-party evidence if VSOE is not available; and lastly our best estimate of selling price for the deliverable if neither VSOE nor third-party evidence is available.
	In order to establish VSOE, we must regularly sell the product or service on a standalone basis with a substantial majority of sales priced within a relatively narrow range. If an insufficient number of standalone sales exist and VSOE cannot be determined, we then consider whether third party evidence can be used to establish selling price. Due to the lack of similar products and services sold by other companies within our industry, we have not established selling price using third-party evidence. If neither VSOE nor third party evidence of selling price exists, we determine our best estimate of selling price using a combination of prices set by our pricing committee adjusted for applicable discounts and customer orders received to date.
	For our collaboration agreement, the process for determining estimates of selling prices of the identifiable deliverables involves significant judgments and estimates to be made by management. Our process considers multiple factors such as estimated headcount, annual research and development budget, estimated length of the research and development period and estimated transfer price on cost, which may vary over time, depending upon the circumstances, and are specific to each deliverable. If the estimated obligation period of one or more deliverables should change, the future amortization of the revenue would also change.
	Deferred service revenue primarily represents product maintenance agreement revenue that is expected to be recognized over the related service period, generally one to three years.
Roche Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue Recognition	Based on ASC Topic 605-28, Revenue Recognition — Milestone Method, we evaluate contingent milestones at inception of the agreement, and recognize consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is considered substantive in its entirety. Milestones are considered substantive if the consideration earned from the achievement of the milestone (i) is consistent with performance required to achieve the milestone or the increase in value to the delivered item, (ii) relates solely to past performance and (iii) is reasonable relative to all of the other deliverables and payments within the arrangement. During August 2014, we achieved the first development milestone and we recorded the related $10.0 million as contractual revenue. Under the terms of the Roche Agreement, we may receive up to an additional $30.0 million based on the achievement of additional development milestones in future periods.

Summary_Of_Significant_Account2

Summary Of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Summary Of Significant Accounting Policies [Abstract]
Summary Of Assets And Liabilities Measured At Fair Value Classified Based On Level Of Input
		December 31, 2014									December 31, 2013
	(in thousands)	Level 1			Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets
	Cash and cash equivalents:
	Cash and money market funds	$	21,952		$	—	$	—	$	21,952	$	12,963	$	—	$	—	$	12,963
	Commercial paper		—			14,497		—		14,497		—		13,399		—		13,399
	Total cash and cash equivalents		21,952			14,497		—		36,449		12,963		13,399		—		26,362
	Investments:
	Commercial paper		—			43,653		—		43,653		—		61,264		—		61,264
	Corporate debt securities		—			8,173		—		8,173		—		8,629		—		8,629
	Asset backed securities		—			13,073		—		13,073		—		16,273		—		16,273
	Total investments		—			64,899		—		64,899		—		86,166		—		86,166
	Total assets measured at fair value	$	21,952		$	79,396	$	—	$	101,348	$	12,963	$	99,565	$	—	$	112,528
	Liabilities
	Financing derivative	$	—		$	—	$	944	$	944	$	—	$	—	$	549	$	549
	Total liabilities measured at fair value	$	—		$	—	$	944	$	944	$	—	$	—	$	549	$	549
Changes In Fair Value Of Financial Derivative
	Financing Derivative		Amount
	Balance as of January 1, 2013		$	—
	Value at issuance			967
	Gain on change in fair value of Financing Derivative			-418
	Balance as of December 31, 2013			549
	Loss on change in fair value of Financing Derivative			395
	Balance as of December 31, 2014		$	944
Estimated Fair Value And Carrying Value of Notes
		December 31, 2014					December 31, 2013
		Fair Value			Carrying Value		Fair Value		Carrying Value
	Long-term notes payable	$	14,817		$	14,124	$	14,551	$	13,347

Cash_Cash_Equivalents_And_Inve1

Cash, Cash Equivalents And Investments (Tables)	12 Months Ended
	Dec. 31, 2014
Cash, Cash Equivalents And Investments [Abstract]
Summary Of Cash, Cash Equivalents And Investments
		As of December 31, 2014
				Gross		Gross
		Amortized		unrealized		unrealized		Fair
		Cost		gains		losses		Value
	Cash and cash equivalents:
	Cash and money market funds	$	21,952	$	—	$	—	$	21,952
	Commercial paper		14,496		1		—		14,497
	Total cash and cash equivalents		36,448		1		—		36,449
	Investments:
	Commercial paper		43,648		5		—		43,653
	Corporate debt securities		8,170		7		-4		8,173
	Asset backed securities		13,073		4		-4		13,073
	Total investments		64,891		16		-8		64,899
	Total cash, cash equivalents and investments	$	101,339	$	17	$	-8	$	101,348
		As of December 31, 2013
				Gross		Gross
		Amortized		unrealized		unrealized		Fair
		Cost		gains		losses		Value
	Cash and cash equivalents:
	Cash and money market funds	$	12,963	$	—	$	—	$	12,963
	Commercial paper		13,398		1		—		13,399
	Total cash and cash equivalents		26,361		1		—		26,362
	Investments:
	Commercial paper		61,252		13		-1		61,264
	Corporate debt securities		8,620		12		-3		8,629
	Asset backed securities		16,281		2		-10		16,273
	Total investments		86,153		27		-14		86,166
	Total cash, cash equivalents and investments	$	112,514	$	28	$	-14	$	112,528
Summary Of Contractual Maturities Of Cash Equivalents And Available-For-Sale Investments
	(in thousands)	Fair Value
	Due in one year or less	$	78,113
	Due after one year through five years		1,283
	Total	$	79,396

Balance_Sheet_Components_Table

Balance Sheet Components (Tables)	12 Months Ended
	Dec. 31, 2014
Balance Sheet Components [Abstract]
Components Of Inventory
		December 31,
	(in thousands)	2014		2013
	Purchased materials	$	3,150	$	3,019
	Work in process		6,115		4,012
	Finished goods		2,070		3,019
	Inventory	$	11,335	$	10,050
Components Of Property And Equipment, Net
		December 31,
	(in thousands)	2014		2013
	Building	$	1,160	$	1,160
	Laboratory equipment and machinery		17,169		16,934
	Leasehold improvements		8,348		8,111
	Computer equipment		4,885		3,885
	Software		4,485		4,457
	Furniture and fixtures		958		926
	Construction in progress		53		12
			37,058		35,485
	Less: Accumulated depreciation		-30,457		-26,249
	Property and equipment, net	$	6,601	$	9,236
Schedule Of Accrued Expenses And Other Current Liabilities
		December 31,
	(in thousands)	2014		2013
	Salaries and benefits	$	6,325	$	5,149
	Accrued license and development services		3,741		1,328
	Inventory accrual, professional services, accrued interest and other		1,375		1,428
	Accrued expenses	$	11,441	$	7,905

Notes_Payable_Tables

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2014
Notes Payable [Abstract]
Schedule Of Debt Payments
	2015	$	1,794
	2016		1,799
	2017		1,794
	2018		5,632
	Thereafter		17,959
	Total remaining payments		28,978
	Less: interest and discounts		-14,854
	Notes payable	$	14,124

Facility_Financing_Tables

Facility Financing (Tables)	12 Months Ended
	Dec. 31, 2014
Facility Financing [Abstract]
Future Minimum Payments Due Under Facility Financing Obligation
	(in thousands)	Financing obligation
	2015	$	668
	Less: interest and discounts		-416
	Total net payments under facility financing obligation		252
	Property reverting to landlord		2,151
	Present value of obligation		2,403
	Less: current portion of obligation		-252
	Long-term portion of obligation	$	2,151

Commitments_And_Contingencies_

Commitments And Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments And Contingencies [Abstract]
Schedule Of Minimum Future Lease Payments Receivable
		Amount
	Years ending December 31,	(in thousands)
	2015	$	3,984
	2016		95
	Total minimum lease payments	$	4,079

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Taxes [Abstract]
Reconciliation Of Federal Income Tax Rate
		Years ended December 31,
		2014		2013		2012
	Statutory tax rate	35.0	%	35.0	%	35.0	%
	State tax rate, net of federal benefit	3.8		2.1		3.9
	Stock-based compensation	-1.3		-1.7		-1.7
	R&D credit	4.0		4.3		1.1
	Other	0		-0.3		-2.1
	Change in valuation allowance	-41.5		-39.4		-36.2
	Effective income tax rate	0.0	%	0.0	%	0.0	%
Reconciliation Of Deferred Tax Assets And Liabilities
		December 31,
	Deferred tax assets:	2014		2013
	Net operating loss carryforwards	$	225,115	$	214,312
	Research and development credits		24,881		22,263
	Depreciation		3,241		3,067
	Accruals and reserves		21,737		7,390
	Total deferred tax assets		274,974		247,032
	Less: Valuation allowance		-273,567		-246,186
	Deferred tax liabilities:
	Deferred rent		-1,407		-846
	Net deferred tax assets	$	—	$	—
Reconciliation Of Unrecognized Tax Benefit Accounts
	Balance as of December 31, 2011	$	9,287
	Increase in balance related to tax positions taken during current year		705
	Balance as of December 31, 2012		9,992
	Increase in balance related to tax positions taken during current year		1,642
	Balance as of December 31, 2013		11,634
	Increase in balance related to tax positions taken in prior year		2,959
	Increase in balance related to tax positions taken during current year		2,359
	Balance as of December 31, 2014	$	16,952

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity [Line Items]
Summary Of Stock Option Activity
				Stock Options Outstanding
		Shares available		Number					Weighted average
		for grant		of shares		Exercise price			exercise price
	Balances, December 31, 2013	3,912		14,070		$	0.20 – 16.00		$	4.81
	Additional shares reserved	3,977
	Options granted	-3,505		3,505		$	4.21 – 7.05		$	6.00
	Options exercised	—		-594		$	0.20 – 6.96		$	2.90
	Options canceled	490		-490		$	1.16 – 15.98		$	5.90
	Balances, December 31, 2014	4,874		16,491		$	0.70 – 16.00		$	5.10
Reconciliation Of Outstanding And Exercisable Stock Options
				Options Outstanding							Options Exercisable
						Weighted average
				Number		remaining contractual		Weighted average			Number	Weighted average
	Exercise price			outstanding		life (Years)		exercise price			vested	exercise price
	$	0.00 – 1.60		1,082,067		6.78		$	1.11		538,693	$	1.04
	$	1.60 – 3.20		4,071,281		6.94		$	2.40		2,489,111	$	2.43
	$	3.20 – 4.80		4,525,775		7.53		$	4.08		2,296,346	$	4.05
	$	4.80 – 6.40		2,459,863		8.74		$	5.62		578,535	$	5.72
	$	6.40 – 8.00		1,654,881		7.68		$	6.99		676,966	$	6.99
	$	8.00 – 9.60		1,125,101		5.04		$	8.50		1,125,101	$	8.50
	$	9.60 – 11.20		354,002		5.35		$	10.80		353,131	$	10.80
	$	11.20 – 12.80		687,610		6.00		$	12.11		560,578	$	12.17
	$	12.80 – 14.40		391,334		5.99		$	13.87		328,010	$	13.83
	$	14.40 – 16.00		139,250		5.87		$	15.99		138,500	$	15.99
				16,491,164		7.20		$	5.10		9,084,971	$	5.60
Schedule Of Stock-Based Compensation Expense
		Years Ended December 31,
		2014			2013			2012
	Cost of revenue	$	758		$	523		$	506
	Research and development		3,785			4,052			4,562
	Sales, general and administrative		5,400			5,330			4,637
	Total stock-based compensation expense	$	9,943		$	9,905		$	9,705
ESPP [Member]
Stockholders' Equity [Line Items]
Schedule Of Fair Value Of Employee Stock Options
			Years Ended December 31,
			2014			2013			2012
	Expected term (years)			0.5 - 2.0			0.5 - 2.0			0.5 - 2.0
	Expected volatility			70.00%			70.00%			90.00%
	Risk-free interest rate			0.1%-0.5%			0.1%-0.4%			0.1%-0.3%
	Dividend yield			—			—			—
Stock Option [Member]
Stockholders' Equity [Line Items]
Schedule Of Fair Value Of Employee Stock Options
			Years Ended December 31,
			2014			2013			2012
	Expected term (years)			6.1 years			6.1 years			6.1 years
	Expected volatility			70.00%			66.80%			63.40%
	Risk-free interest rate			1.90%			1.30%			1.00%
	Dividend yield			—			—			—

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Net Loss Per Share [Abstract]
Computation Of Basic And Diluted Net Loss Per Share
		Years Ended December 31,
		2014			2013		2012
	Numerator:
	Net loss	$	-66,160		$	-79,293	$	-94,465
	Denominator:
	Weighted average shares used in computation of basic and diluted net loss per share		70,475			62,784		55,733
	Basic and diluted net loss per share	$	-0.94		$	-1.26	$	-1.69
Anti-Dilutive Shares Excluded From Computation Of Diluted Net Loss Per Share
		Years Ended December 31,
	(in thousands)	2014		2013		2012
	Options outstanding	16,491		14,070		12,016
	Warrants to purchase common stock	5,500		5,500		10

Segment_And_Geographic_Informa1

Segment And Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2014
Segment And Geographic Information [Abstract]
Schedule Of Revenue By Geographic Location
		Years Ended December 31,
	(in millions)	2014		2013		2012
	United States	$	34.8	$	13.6	$	11.4
	Europe		10.1		9.2		6.6
	Asia		15.7		5.4		8.0
	Total	$	60.6	$	28.2	$	26.0

Unaudited_Selected_Quarterly_F1

Unaudited Selected Quarterly Financial Data (Tables)	12 Months Ended
	Dec. 31, 2014
Unaudited Selected Quarterly Financial Data [Abstract]
Schedule Of Unaudited Quarterly Financial Data
		Fiscal 2014 Quarter Ended
	(in thousands, except per share data)	March 31,			June 30,		September 30,			December 31,
	Total revenue	$	11,642		$	11,425	$	20,623		$	16,904
	Total gross profit		2,676			3,126		13,162	-1		4,438
	Total operating expenses		20,921			21,428		21,575			22,332
	Loss from operations		-18,245			-18,302		-8,413	-1		-17,894
	Net loss		-18,886			-19,136		-9,163			-18,975
	Basic and diluted net loss per share	$	-0.28		$	-0.27	$	-0.13		$	-0.26
		Fiscal 2013 Quarter Ended
		March 31,			June 30,		September 30,			December 31,
	Total revenue	$	5,578		$	6,048	$	7,421		$	9,134
	Total gross profit		930			1,059		1,241			3,189
	Total operating expenses		21,537			21,056		21,176			20,193
	Loss from operations		-20,607			-19,997		-19,935			-17,004
	Net loss		-21,104			-20,471		-20,487			-17,231
	Basic and diluted net loss per share	$	-0.37		$	-0.33	$	-0.31		$	-0.26
		-1		During the third quarter ended September 30, 2014, we achieved the first development milestone as provided in the Roche Agreement and we recorded the related $10.0 million as contractual revenue. See “Note 3. Contractual Revenue”  for additional information.

Summary_Of_Significant_Account3

Summary Of Significant Accounting Policies (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Summary Of Significant Accounting Policies [Line Items]
Fair value assets liabilities transfer between levels	$0
Impairment charges on investments	0	0	0
Highly liquid investments considered to be cash equivalents, maximum maturity		3 months
Net accounts receivable from customers, description	As of December 31, 2014, three customers each represented more than 10% of our net accounts receivable.	As of December 31, 2013, one customer represented 37% of our net accounts receivable. No other customer represented more than 10% of our net accounts receivable as of December 31, 2013.
Accounts Receivable [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of individual customers	3	1
Accounts Receivable [Member] | Domestic Customers [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	58.00%	39.00%
Accounts Receivable [Member] | Customer D [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage		37.00%
Other Current Liabilities [Member]
Summary Of Significant Accounting Policies [Line Items]
Reclassification		1,900,000
Other Items [Member]
Summary Of Significant Accounting Policies [Line Items]
Reclassification		$66,000	$1,008,000
Lab Equipment [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful life	3 years
Building [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful life	30 years
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Future cash flows weighted average market yield	19.50%
Product maintenance agreement service period	1 year
Minimum [Member] | Accounts Receivable [Member] | Customer A [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	10.00%
Minimum [Member] | Accounts Receivable [Member] | Customer B [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	10.00%
Minimum [Member] | Accounts Receivable [Member] | Customer C [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	10.00%
Minimum [Member] | Computer Equipment [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful life	2 years
Minimum [Member] | Software [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful life	3 years
Minimum [Member] | Furniture and Fixtures [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful life	3 years
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Future cash flows weighted average market yield	20.40%	20.40%
Product maintenance agreement service period	3 years
Maximum [Member] | Computer Equipment [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful life	3 years
Maximum [Member] | Software [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful life	5 years
Maximum [Member] | Furniture and Fixtures [Member]
Summary Of Significant Accounting Policies [Line Items]
Property and equipment estimated useful life	7 years
Roche Agreement [Member] | Minimum [Member] | Sales Revenue, Net [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	10.00%

Summary_Of_Significant_Account4

Summary Of Significant Accounting Policies (Summary Of Assets And Liabilities Measured At Fair Value Classified Based On Level Of Input) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Assets
Total assets measured at fair value	$101,348	$112,528
Liabilities
Total liabilities measured at fair value	944	549
Financing Derivative [Member]
Liabilities
Total liabilities measured at fair value	944	549
Cash And Cash Equivalents [Member]
Assets
Total cash and cash equivalents	36,449	26,362
Cash And Cash Equivalents [Member] | Cash And Money Market Funds [Member]
Assets
Total cash and cash equivalents	21,952	12,963
Cash And Cash Equivalents [Member] | Commercial Paper [Member]
Assets
Total cash and cash equivalents	14,497	13,399
Investments [Member]
Assets
Total investments	64,899	86,166
Investments [Member] | Commercial Paper [Member]
Assets
Total investments	43,653	61,264
Investments [Member] | Corporate Debt Securities [Member]
Assets
Total investments	8,173	8,629
Investments [Member] | Asset Backed Securities [Member]
Assets
Total investments	13,073	16,273
Level 1 [Member]
Assets
Total assets measured at fair value	21,952	12,963
Level 1 [Member] | Cash And Cash Equivalents [Member]
Assets
Total cash and cash equivalents	21,952	12,963
Level 1 [Member] | Cash And Cash Equivalents [Member] | Cash And Money Market Funds [Member]
Assets
Total cash and cash equivalents	21,952	12,963
Level 2 [Member]
Assets
Total assets measured at fair value	79,396	99,565
Level 2 [Member] | Cash And Cash Equivalents [Member]
Assets
Total cash and cash equivalents	14,497	13,399
Level 2 [Member] | Cash And Cash Equivalents [Member] | Commercial Paper [Member]
Assets
Total cash and cash equivalents	14,497	13,399
Level 2 [Member] | Investments [Member]
Assets
Total investments	64,899	86,166
Level 2 [Member] | Investments [Member] | Commercial Paper [Member]
Assets
Total investments	43,653	61,264
Level 2 [Member] | Investments [Member] | Corporate Debt Securities [Member]
Assets
Total investments	8,173	8,629
Level 2 [Member] | Investments [Member] | Asset Backed Securities [Member]
Assets
Total investments	13,073	16,273
Level 3 [Member]
Liabilities
Total liabilities measured at fair value	944	549
Level 3 [Member] | Financing Derivative [Member]
Liabilities
Total liabilities measured at fair value	$944	$549

Summary_Of_Significant_Account5

Summary Of Significant Accounting Policies (Changes In Fair Value Of Financial Derivative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policies [Abstract]
Beginning balance	$549
Value at issuance		967
Gain (loss) on change in estimated fair value	395	-418
Ending balance	$944	$549

Summary_Of_Significant_Account6

Summary Of Significant Accounting Policies (Estimated Fair Value And Carrying Value Of Notes) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Long-term notes payable	$14,817	$14,551
Carrying Value [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Long-term notes payable	$14,124	$13,347

Contractual_Revenue_Details

Contractual Revenue (Details) (Roche Agreement [Member], USD $)	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Roche Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non-refundable upfront payment		$35
Deferred revenue, revenue recognized		6.8	1.7
Deferred revenue		26.5
Maximum potential for additional payments to be recognized upon the achievement of certain development milestones		40
Additional payment based upon achievements of milestones	10	10
Remaining potential for additional payments to be recognized upon the achievement of certain development milestones		$30

Cash_Cash_Equivalents_And_Inve2

Cash, Cash Equivalents And Investments (Summary Of Cash And Cash Equivalents And Investments) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$101,339
Gross unrealized gains	17
Gross unrealized losses	-8
Fair Value	101,348
Cash And Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	36,448	26,361
Gross unrealized gains	1	1
Fair Value	36,449	26,362
Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	64,891
Gross unrealized gains	16
Gross unrealized losses	-8
Fair Value	64,899
Cash And Money Market Funds [Member] | Cash And Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	21,952	12,963
Fair Value	21,952	12,963
Commercial Paper [Member] | Cash And Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	14,496	13,398
Gross unrealized gains	1	1
Fair Value	14,497	13,399
Commercial Paper Not Included With Cash And Cash Equivalents [Member] | Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	43,648	61,252
Gross unrealized gains	5	13
Gross unrealized losses		-1
Fair Value	43,653	61,264
Corporate Debt Securities [Member] | Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	8,170	8,620
Gross unrealized gains	7	12
Gross unrealized losses	-4	-3
Fair Value	8,173	8,629
Asset Backed Securities [Member] | Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	13,073	16,281
Gross unrealized gains	4	2
Gross unrealized losses	-4	-10
Fair Value	13,073	16,273
Certificates Of Deposits [Member] | Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		86,153
Gross unrealized gains		27
Gross unrealized losses		-14
Fair Value		86,166
U.S. Government And Agency Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		112,514
Gross unrealized gains		28
Gross unrealized losses		-14
Fair Value		$112,528

Cash_Cash_Equivalents_And_Inve3

Cash, Cash Equivalents And Investments (Summary Of Contractual Maturities Of Cash Equivalents And Available-For-Sale Investments) (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Cash, Cash Equivalents And Investments [Abstract]
Due in one year or less	$78,113
Due after one year through five years	1,283
Total	$79,396

Balance_Sheet_Components_Narra

Balance Sheet Components (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Balance Sheet Components [Abstract]
Depreciation expense	$4,221	$5,648	$6,649

Balance_Sheet_Components_Compo

Balance Sheet Components (Components Of Inventory) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Purchased materials, net	$3,150	$3,019
Work in process, net	6,115	4,012
Finished goods, net	2,070	3,019
Inventory, net	$11,335	$10,050

Balance_Sheet_Components_Compo1

Balance Sheet Components (Components Of Property and Equipment, Net) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Property and equipment	$37,058	$35,485
Less: Accumulated depreciation	-30,457	-26,249
Property and equipment, net	6,601	9,236
Building [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	1,160	1,160
Laboratory Equipment And Machinery [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	17,169	16,934
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	8,348	8,111
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	4,885	3,885
Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	4,485	4,457
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	958	926
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$53	$12

Balance_Sheet_Components_Sched

Balance Sheet Components (Schedule Of Accrued Expenses And Other Current Liabilities) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Balance Sheet Components [Abstract]
Salaries and benefits	$6,325	$5,149
Accrued license and development services	3,741	1,328
Inventory accrual, professional services, accrued interest and other	1,375	1,428
Accrued expenses and other current liabilities	$11,441	$7,905

Notes_Payable_Details

Notes Payable (Details) (USD $)	1 Months Ended
	Feb. 28, 2013	Dec. 31, 2014	Dec. 31, 2013	Feb. 05, 2013
Debt Instrument [Line Items]
Principal amount of notes	$14,100,000
Purchase shares of common stock	5,500,000			5,500,000
Common stock aggregate exercise price	$2.63	$2.63		$2.63
Cash and cash equivalent minimum amount quarterly required	2,000,000
Fair value of the financing derivative		944,000	549,000
Fair value of the warrants	6,400,000
Allocation of notes calculated on a relative fair value basis	20,500,000
Long-term notes payable, Carrying Value	12,800,000	14,124,000	13,347,000
Additional discount allocated to the warrants	7,700,000
Remaining discount yet to be amortized		6,400,000
Deerfield Promissory Notes [Member]
Debt Instrument [Line Items]
Principal amount of notes	$20,500,000
Debt instrument, stated interest rate	8.75%
Minimum [Member]
Debt Instrument [Line Items]
Future cash flows weighted average market yield		19.50%
Maximum [Member]
Debt Instrument [Line Items]
Future cash flows weighted average market yield		20.40%	20.40%

Notes_Payable_Schedule_Of_Debt

Notes Payable (Schedule Of Debt Payments) (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Notes Payable [Abstract]
2015	$1,794
2016	1,799
2017	1,794
2018	5,632
Thereafter	17,959
Total remaining payments	28,978
Less: interest and discounts	-14,854
Total debt payments	$14,124

Facility_Financing_Narrative_D

Facility Financing (Narrative) (Details) (USD $)	Dec. 31, 2014
In Millions, unless otherwise specified
Facility Financing and Debt Obligations (Textual) [Abstract]
Tenant improvement allowance	$1.80
Building and leasehold improvement assets	3
Fair value of the facility prior to commencing renovations	1.2
Landlord incentives within property and equipment, net	$1.80

Facility_Financing_Future_Mini

Facility Financing (Future Minimum Payments Due Under Facility Financing Obligation) (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Future minimum payments due under the facility financing obligation
2015	$668
Less: interest and discounts	-416
Total net payments under facility financing obligation	252
Property reverting to landlord	2,151
Present value of obligation	2,403
Less: current portion of obligation	-252
Long-term portion of obligation	$2,151

Commitments_And_Contingencies_1

Commitments And Contingencies (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Commitments And Contingencies [Abstract]
Rent expense	$2,200,000	$2,300,000	$2,400,000
Other commitments estimated amount	13,600,000
Additional liability associated with indemnification obligations	$0

Commitments_And_Contingencies_2

Commitments And Contingencies (Schedule Of Minimum Future Lease PaymentsRemaining) (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Schedule of minimum future lease payments receivable
2015	$3,984
2016	95
Total minimum lease payments	$4,079

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Taxes [Line Items]
Increase in valuation allowance	$27,400,000	$31,900,000
Benefit of federal net operating loss deferred tax assets	4,100,000
Benefit of state net operating loss deferred tax assets	600,000
Total unrecognized tax benefit	16,952,000	11,634,000	9,992,000	9,287,000
Period of increase or decrease in total amount of unrecognized income tax benefits	12 months
Accrued interest or penalties	0	0
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	579,700,000
Net operating loss carryforward, expiration	2024
Research and development credit carryforward	21,000,000
Research and developmen tax credit carryforward, expiration	2024
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Net operating loss carryforwards	526,600,000
Net operating loss carryforward, expiration	2014
Research and development credit carryforward	$22,300,000

Income_Taxes_Reconciliation_Of

Income Taxes (Reconciliation Of Federal Income Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Abstract]
Statutory tax rate	35.00%	35.00%	35.00%
State tax rate, net of federal benefit	3.80%	2.10%	3.90%
Stock-based compensation	-1.30%	-1.70%	-1.70%
Federal R&D credit	4.00%	4.30%	1.10%
Other	0.00%	-0.30%	-2.10%
Change in valuation allowance	-41.50%	-39.40%	-36.20%
Effective income tax rate	0.00%	0.00%	0.00%

Income_Taxes_Reconciliation_Of1

Income Taxes (Reconciliation Of Deferred Tax Assets And Liabilities) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred tax assets:
Net operating loss carryforwards	$225,115	$214,312
Research and development credits	24,881	22,263
Depreciation	3,241	3,067
Accruals and reserves	21,737	7,390
Total deferred tax assets	274,974	247,032
Less: Valuation allowance	-273,567	-246,186
Deferred tax liabilities:
Deferred Rent	-1,407	-846
Net deferred tax assets

Income_Taxes_Reconciliation_Of2

Income Taxes (Reconciliation Of Unrecognized Tax Benefit Accounts) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Abstract]
Unrecognized tax benefit, beginning balance	$11,634	$9,992	$9,287
Increase in balance related to tax positions taken in prior year	2,959
Increase in balance related to tax positions taken during current year	2,359	1,642	705
Unrecognized tax benefit, ending balance	$16,952	$11,634	$9,992

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)	12 Months Ended			1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jan. 31, 2015	Feb. 28, 2013	Feb. 05, 2013	Oct. 31, 2010	Feb. 03, 2015
	item
Stockholders' Equity [Line Items]
Common Stock, shares authorized	1,000,000,000	1,000,000,000					1,000,000,000
Common Stock, par value	$0.00	$0.00					$0.00
Preferred Stock, shares authorized	50,000,000	50,000,000					50,000,000
Preferred Stock, par value	$0.00	$0.00					$0.00
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common stock, dividends declared	$0
Voting right of common stock share holders	The holder of each share of common stock is entitled to one vote.
Voting right of common stock share holdes, number of votes	1
Purchase shares of common stock					5,500,000	5,500,000
Common stock aggregate exercise price	$2.63				$2.63	$2.63
Purchase shares of common stock, outstanding	5,500,000
Number of equity compensation plans	3
Aggregate intrinsic value outstanding	$53,300,000
Aggregate intrinsic value exercisable options	27,600,000
Stock price	$7.84
Weighted average remaining contractual life for exercisable	6 years 2 months 19 days
Total intrinsic value of options exercised	2,000,000	500,000	700,000
Fair value of options vested	6,000,000	6,500,000	2,300,000
Stock-based compensation	9,943,000	9,905,000	9,705,000
2010 Plan [Member]
Stockholders' Equity [Line Items]
Stock option grant, term	10 years
Stock option grant, vest	4 years
Stock option grant, vest rate upon first anniversary	25.00%
Stock option grant, vest rate per month thereafter	2.08%
Common stock reserved for issuance	4,900,000	700,000
Additional common stock reserved for issuance				3,700,000
2010 Director Plan [Member]
Stockholders' Equity [Line Items]
Stock option grant, term	10 years
Stock option grant, vest rate upon first anniversary	33.00%
Stock option grant, vest rate per month thereafter	2.78%
2010 Director Plan [Member] | Minimum [Member]
Stockholders' Equity [Line Items]
Stock option grant, vest	1 year
2010 Director Plan [Member] | Maximum [Member]
Stockholders' Equity [Line Items]
Stock option grant, vest	3 years
ESPP [Member]
Stockholders' Equity [Line Items]
Common stock reserved for issuance	0
Additional common stock reserved for issuance				1,500,000
Number of purchase periods		4
Purchase period of ESPP		6 months
Percentage of fair market value at which stock can be purchased		85.00%
Weighted average fair value at grant date	$2.98	$1.76	$1.38
Stock-based compensation	2,100,000	2,800,000	2,800,000
Common stock purchased under plan	1,325,507	1,519,366	832,878
Cash received from option exercises	2,300,000	2,600,000	2,100,000
At The Market Offering [Member]
Stockholders' Equity [Line Items]
Common stock offering price Cantor shares		30,000,000	30,000,000
Commissions to Cantor	3.00%
Shares issued	5,800,000
Average common stock price per share	$6.81
Stock Option [Member]
Stockholders' Equity [Line Items]
Percentage of outstanding common stock used to determine annual plan increase	2.00%
Weighted average remaining contractual life		2 years 9 months 18 days
Weighted average fair value at grant date	$3.81	$1.80	$1.84
Stock-based compensation	7,800,000	7,000,000	6,900,000
Unrecognized compensation costs		15,400,000
Cash received from option exercises	1,600,000	500,000	600,000
Subsequent Event [Member] | At The Market Offering [Member]
Stockholders' Equity [Line Items]
Common stock offering price Cantor shares								$30,000,000

Stockholders_Equity_Summary_Of

Stockholders' Equity (Summary Of Stock Option Activity) (Details) (Stock Option [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Additional shares reserved, Shares available for grant	3,977,000
$0.20 - 16.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balances, December 31, 2014, Shares available for grant	3,912,000
Balances, December 31, 2014, Number of shares	14,070,000
Exercise price, lower range	0.2
Exercise price, upper range	16
Balances, December 31, 2014, Weighted average exercise price per share	4.81
$4.21 - 7.05 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options granted, Shares available for grant		-3,505,000
Options granted, Number of shares		3,505,000
Exercise price, lower range		$4.21
Exercise price, upper range		$7.05
Options granted, Weighted average exercise price per share		$6
$0.20 - 6.96 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options exercised, Number of shares		-594,000
Exercise price, lower range		$0.20
Exercise price, upper range		$6.96
Options exercised, Weighted average exercise price per share		$2.90
$1.16 b 15.98 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options canceled, Shares available for grant		490,000
Options canceled, Number of shares		-490,000
Exercise price, lower range		$1.16
Exercise price, upper range		$15.98
Options canceled, Weighted average exercise price per share		$5.90
$0.70 -16.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balances, December 31, 2014, Shares available for grant		4,874,000
Balances, December 31, 2014, Number of shares		16,491,000
Exercise price, lower range		$0.70
Exercise price, upper range		$16
Balances, December 31, 2014, Weighted average exercise price per share		$5.10

Stockholders_Equity_Reconcilia

Stockholders' Equity (Reconciliation Of Outstanding And Exercisable Stock Options) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Number outstanding	16,491,164
Weighted average remaining contractual life	7 years 2 months 12 days
Weighted average exercise price	$5.10
Number vested	9,084,971
Weighted average exercise price, vested	$5.60
$0.00 - 1.60 [Member]
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price, lower range	$0
Exercise price, upper range	$1.60
Number outstanding	1,082,067
Weighted average remaining contractual life	6 years 9 months 11 days
Weighted average exercise price	$1.11
Number vested	538,693
Weighted average exercise price, vested	$1.04
$1.60 - 3.20 [Member]
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price, lower range	$1.60
Exercise price, upper range	$3.20
Number outstanding	4,071,281
Weighted average remaining contractual life	6 years 11 months 9 days
Weighted average exercise price	$2.40
Number vested	2,489,111
Weighted average exercise price, vested	$2.43
$3.20 - 4.80 [Member]
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price, lower range	$3.20
Exercise price, upper range	$4.80
Number outstanding	4,525,775
Weighted average remaining contractual life	7 years 6 months 11 days
Weighted average exercise price	$4.08
Number vested	2,296,346
Weighted average exercise price, vested	$4.05
$4.80 - 6.40 [Member]
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price, lower range	$4.80
Exercise price, upper range	$6.40
Number outstanding	2,459,863
Weighted average remaining contractual life	8 years 8 months 27 days
Weighted average exercise price	$5.62
Number vested	578,535
Weighted average exercise price, vested	$5.72
$6.40 - 8.00 [Member]
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price, lower range	$6.40
Exercise price, upper range	$8
Number outstanding	1,654,881
Weighted average remaining contractual life	7 years 8 months 5 days
Weighted average exercise price	$6.99
Number vested	676,966
Weighted average exercise price, vested	$6.99
$8.00 - 9.60 [Member]
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price, lower range	$8
Exercise price, upper range	$9.60
Number outstanding	1,125,101
Weighted average remaining contractual life	5 years 15 days
Weighted average exercise price	$8.50
Number vested	1,125,101
Weighted average exercise price, vested	$8.50
$9.60 - 11.20 [Member]
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price, lower range	$9.60
Exercise price, upper range	$11.20
Number outstanding	354,002
Weighted average remaining contractual life	5 years 4 months 6 days
Weighted average exercise price	$10.80
Number vested	353,131
Weighted average exercise price, vested	$10.80
$11.20 - 12.80 [Member]
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price, lower range	$11.20
Exercise price, upper range	$12.80
Number outstanding	687,610
Weighted average remaining contractual life	6 years
Weighted average exercise price	$12.11
Number vested	560,578
Weighted average exercise price, vested	$12.17
$12.80 - 14.40 [Member]
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price, lower range	$12.80
Exercise price, upper range	$14.40
Number outstanding	391,334
Weighted average remaining contractual life	5 years 11 months 27 days
Weighted average exercise price	$13.87
Number vested	328,010
Weighted average exercise price, vested	$13.83
$14.40 - 16.00 [Member]
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise price, lower range	$14.40
Exercise price, upper range	$16
Number outstanding	139,250
Weighted average remaining contractual life	5 years 10 months 13 days
Weighted average exercise price	$15.99
Number vested	138,500
Weighted average exercise price, vested	$15.99

Stockholders_Equity_Schedule_O

Stockholders' Equity (Schedule Of Stock-Based Compensation Expense) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$9,943	$9,905	$9,705
Cost Of Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	758	523	506
Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	3,785	4,052	4,562
Sales, General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$5,400	$5,330	$4,637

Stockholders_Equity_Schedule_O1

Stockholders' Equity (Schedule Of Fair Value Of Employee Stock Options) (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
ESPP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility	70.00%	70.00%	90.00%
Risk-free interest rate, minimum	0.10%	0.10%	0.10%
Risk-free interest rate, maximum	0.50%	0.40%	0.30%
Dividend yield
ESPP [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	6 months	6 months	6 months
ESPP [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	2 years	2 years	2 years
Stock Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	6 years 1 month 6 days	6 years 1 month 6 days	6 years 1 month 6 days
Expected volatility	70.00%	66.80%	63.40%
Risk-free interest rate	1.90%	1.30%	1.00%
Dividend yield

Net_Loss_Per_Share_Computation

Net Loss Per Share (Computation Of Basic And Diluted Net Loss Per Share) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Numerator
Net loss	($18,975)	($9,163)	($19,136)	($18,886)	($17,231)	($20,487)	($20,471)	($21,104)	($66,160)	($79,293)	($94,465)
Denominator:
Weighted average shares used in computation of basic and diluted net loss per share									70,475	62,784	55,733
Basic and diluted net loss per share									($0.94)	($1.26)	($1.69)

Net_Loss_Per_Share_AntiDilutiv

Net Loss Per Share (Anti-Dilutive Shares Excluded From Computation Of Diluted Net Loss Per Share) (Details)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock Option [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Stock excluded from the computation of diluted net loss per share	16,491	14,070	12,016
Warrants To Purchase Common Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Stock excluded from the computation of diluted net loss per share	5,500	5,500	10

Segment_And_Geographic_Informa2

Segment And Geographic Information (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
									segment
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of reportable segments									1
Revenue	$16,904	$20,623	$11,425	$11,642	$9,134	$7,421	$6,048	$5,578	$60,594	$28,181	$25,983
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue									34,800	13,600	11,400
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue									10,100	9,200	6,600
Asia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue									$15,700	$5,400	$8,000

Unaudited_Selected_Quarterly_F2

Unaudited Selected Quarterly Financial Data (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information [Line Items]
Total revenue	$16,904,000	$20,623,000	$11,425,000	$11,642,000	$9,134,000	$7,421,000	$6,048,000	$5,578,000	$60,594,000	$28,181,000	$25,983,000
Total gross profit (loss)	4,438,000	13,162,000	3,126,000	2,676,000	3,189,000	1,241,000	1,059,000	930,000	23,402,000	6,419,000	940,000
Total operating expenses	22,332,000	21,575,000	21,428,000	20,921,000	20,193,000	21,176,000	21,056,000	21,537,000	86,256,000	83,962,000	95,278,000
Operating loss	-17,894,000	-8,413,000	-18,302,000	-18,245,000	-17,004,000	-19,935,000	-19,997,000	-20,607,000	-62,854,000	-77,543,000	-94,338,000
Net loss	-18,975,000	-9,163,000	-19,136,000	-18,886,000	-17,231,000	-20,487,000	-20,471,000	-21,104,000	-66,160,000	-79,293,000	-94,465,000
Basic and diluted net loss per share	($0.26)	($0.13)	($0.27)	($0.28)	($0.26)	($0.31)	($0.33)	($0.37)
Roche Agreement [Member]
Quarterly Financial Information [Line Items]
Additional payment based upon achievements of milestones		$10,000,000							$10,000,000